{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:25:09Z","timestamp":1793118309557,"version":"4.5.0"},"reference-count":431,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T00:00:00Z","timestamp":1768089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01775-2","type":"journal-article","created":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T05:54:13Z","timestamp":1768110853000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Molecularly targeted therapy and immunotherapy in leukemias"],"prefix":"10.1186","volume":"19","author":[{"given":"Elie","family":"Cousin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Picard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Oundjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Tardif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Quemener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Ga\u00eblle","family":"Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Dominique","family":"Galibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Gandemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Mazurier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,11]]},"reference":[{"issue":"1","key":"1775_CR1","first-page":"177","volume":"24","author":"K Wong","year":"1995","unstructured":"Wong K, Lim HL, Teo CP, Tan YO, Kueh YK. Treatment of acute promyelocytic leukaemia in first relapse with all-trans retinoic acid. Ann Acad Med Singapore. 1995;24(1):177\u20139.","journal-title":"Ann Acad Med Singapore"},{"issue":"9","key":"1775_CR2","first-page":"731","volume":"89","author":"AS Davis","year":"2014","unstructured":"Davis AS, Viera AJ, Mead MD. Leukemia: an overview for primary care. Am Fam Physician. 2014;89(9):731\u20138.","journal-title":"Am Fam Physician"},{"issue":"1","key":"1775_CR3","volume":"2015","author":"H Ma","year":"2015","unstructured":"Ma H, Mallampati S, An G, Wang J. Targeted therapy in hematological malignancies: from basic research to clinical practice. BioMed Res Int. 2015;2015(1):157570.","journal-title":"BioMed Res Int"},{"issue":"9","key":"1775_CR4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3389\/fonc.2019.00655","volume":"23","author":"MT Voso","year":"2019","unstructured":"Voso MT, Ottone T, Lavorgna S, Venditti A, Maurillo L, Lo-Coco F, et al. MRD in AML: the role of new techniques. Front Oncol. 2019;23(9):655.","journal-title":"Front Oncol"},{"issue":"2","key":"1775_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.beha.2019.05.008","volume":"32","author":"VA Guerra","year":"2019","unstructured":"Guerra VA, DiNardo C, Konopleva M. Venetoclax-based therapies for acute myeloid leukemia. Best Pract Res Clin Haematol. 2019;32(2):145\u201353.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"12","key":"1775_CR6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"15","key":"1775_CR7","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1200\/JCO.23.01061","volume":"42","author":"ES Wang","year":"2024","unstructured":"Wang ES, Goldberg AD, Tallman M, Walter RB, Karanes C, Sandhu K, et al. Crenolanib and intensive chemotherapy in adults with newly diagnosed FLT3-mutated AML. J Clin Oncol. 2024;42(15):1776\u201387.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1775_CR8","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a flt3 mutation. N Engl J Med. 2017;377(5):454\u201364.","journal-title":"N Engl J Med"},{"issue":"18","key":"1775_CR9","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728\u201340.","journal-title":"N Engl J Med"},{"issue":"10388","key":"1775_CR10","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, \u017d\u00e1k P, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2023;401(10388):1571\u201383.","journal-title":"Lancet Lond Engl"},{"issue":"8","key":"1775_CR11","doi-asserted-by":"publisher","first-page":"e600","DOI":"10.1016\/S2352-3026(23)00117-5","volume":"10","author":"L Xuan","year":"2023","unstructured":"Xuan L, Wang Y, Yang K, Shao R, Huang F, Fan Z, et al. Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2023;10(8):e600\u201311.","journal-title":"Lancet Haematol"},{"issue":"14","key":"1775_CR12","doi-asserted-by":"publisher","first-page":"1441254","DOI":"10.3389\/fonc.2024.1441254","volume":"19","author":"G Sapienza","year":"2024","unstructured":"Sapienza G, Castronovo M, Tringali S, Bono R, Rotolo C, Mul\u00e8 A, et al. Sorafenib maintenance after allogeneic stem cell transplantation in patients with FLT3+ AML receiving midostaurin during induction and consolidation: A retrospective analysis. Front Oncol. 2024;19(14):1441254.","journal-title":"Front Oncol"},{"issue":"23","key":"1775_CR13","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1182\/blood.2023020301","volume":"142","author":"S Loo","year":"2023","unstructured":"Loo S, Roberts AW, Anstee NS, Kennedy GA, He S, Schwarer AP, et al. Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: A randomized, placebo-controlled study by the ALLG. Blood. 2023;142(23):1960\u201371.","journal-title":"Blood"},{"issue":"1","key":"1775_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13045-020-00992-1","volume":"13","author":"MT Gebru","year":"2020","unstructured":"Gebru MT, Wang HG. Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia. J Hematol OncolJ Hematol Oncol. 2020;13(1):155.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"35","key":"1775_CR15","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1200\/JCO.22.00602","volume":"40","author":"N Daver","year":"2022","unstructured":"Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, et al. Venetoclax plus gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 2022;40(35):4048\u201359.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"Supplement 1","key":"1775_CR16","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1182\/blood-2022-157210","volume":"140","author":"N Short","year":"2022","unstructured":"Short N, DiNardo CD, Daver N, Macaron W, Yilmaz M, Borthakur G, et al. Updated results from a phase I\/II study of the triplet combination of azacitidine, venetoclax and gilteritinib for patients with FLT3-mutated acute myeloid leukemia. Blood. 2022;140(Supplement 1):2007\u20139.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1775_CR17","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1182\/blood-2024-204296","volume":"144","author":"M Yilmaz","year":"2024","unstructured":"Yilmaz M, Muftuoglu M, Short NJ, Loghavi S, Kadia TM, DiNardo CD, et al. Phase I\/II study of quizartinib, venetoclax, and decitabine triple combination in FLT3-ITD mutated AML. Blood. 2024;144(Supplement 1):4263.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1775_CR18","doi-asserted-by":"publisher","first-page":"9029","DOI":"10.1182\/blood-2022-159110","volume":"140","author":"F Ong","year":"2022","unstructured":"Ong F, Short N, Daver N, Kadia TM, DiNardo CD, Yilmaz M, et al. A Phase I\/II study of combination of ASTX727, gilteritinib and venetoclax in patients with relapsed\/refractory FLT3 mutated acute myeloid leukemia (AML) and frontline FLT3 mutated AML patients unfit for chemotherapy. Blood. 2022;140(Supplement 1):9029\u201331.","journal-title":"Blood"},{"issue":"1","key":"1775_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40164-025-00605-y","volume":"14","author":"M Yao","year":"2025","unstructured":"Yao M, Yan W, Wang Y, Zhao Y, Xu X, Chen Y, et al. IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response. Exp Hematol Oncol. 2025;14(1):15.","journal-title":"Exp Hematol Oncol"},{"issue":"16","key":"1775_CR20","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022;386(16):1519\u201331.","journal-title":"N Engl J Med"},{"issue":"4","key":"1775_CR21","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/2643-3230.BCD-22-0205","volume":"4","author":"CA Lachowiez","year":"2023","unstructured":"Lachowiez CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, et al. A Phase Ib\/II study of ivosidenib with venetoclax \u00b1 azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discov. 2023;4(4):276\u201393.","journal-title":"Blood Cancer Discov"},{"issue":"Supplement 1","key":"1775_CR22","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1182\/blood-2024-201710","volume":"144","author":"JE Cortes","year":"2024","unstructured":"Cortes JE, Roboz GJ, Watts JM, Baer MR, Jonas BA, Schiller GJ, et al. Combination of olutasidenib and azacitidine induces durable complete remissions in mIDH1 acute myeloid leukemia: A multicohort open-label phase 1\/2 trial. Blood. 2024;144(Supplement 1):2886.","journal-title":"Blood"},{"issue":"7","key":"1775_CR23","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1002\/cncr.23789","volume":"113","author":"A Raza","year":"2008","unstructured":"Raza A, Mehdi M, Mumtaz M, Ali F, Lascher S, Galili N. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer. 2008;113(7):1596\u2013604.","journal-title":"Cancer"},{"issue":"5","key":"1775_CR24","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/leu.2011.294","volume":"26","author":"DA Pollyea","year":"2012","unstructured":"Pollyea DA, Kohrt HE, Gallegos L, Figueroa ME, Abdel-Wahab O, Zhang B, et al. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia. 2012;26(5):893\u2013901.","journal-title":"Leukemia"},{"issue":"7","key":"1775_CR25","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and Venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"issue":"22","key":"1775_CR26","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1182\/blood.2025028825","volume":"145","author":"TL Lin","year":"2025","unstructured":"Lin TL. Are you ready for it? VEN-HMA for younger patients with AML. Blood. 2025;145(22):2543\u20134.","journal-title":"Blood"},{"issue":"17","key":"1775_CR27","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1182\/blood.2021014586","volume":"140","author":"ES Wang","year":"2022","unstructured":"Wang ES, Montesinos P, Minden MD, Lee JH, Heuser M, Naoe T, et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. Blood. 2022;140(17):1845\u201357.","journal-title":"Blood"},{"issue":"11","key":"1775_CR28","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","volume":"22","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, Schuh AC, Stein EM, Montesinos P, Wei AH, de Botton S, et al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): A single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol. 2021;22(11):1597\u2013608.","journal-title":"Lancet Oncol"},{"issue":"14","key":"1775_CR29","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1200\/JCO.20.02342","volume":"39","author":"T Cluzeau","year":"2021","unstructured":"Cluzeau T, Sebert M, Rahm\u00e9 R, Cuzzubbo S, Lehmann-Che J, Madelaine I, et al. Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the groupe francophone des my\u00e9lodysplasies (GFM). J Clin Oncol. 2021;39(14):1575\u201383.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1775_CR30","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1016\/S2352-3026(22)00403-3","volume":"10","author":"G Garcia-Manero","year":"2023","unstructured":"Garcia-Manero G, Goldberg AD, Winer ES, Altman JK, Fathi AT, Odenike O, et al. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. Lancet Haematol. 2023;10(4):e272\u201383.","journal-title":"Lancet Haematol"},{"issue":"5","key":"1775_CR31","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1182\/blood.2024027408","volume":"146","author":"JF Zeidner","year":"2025","unstructured":"Zeidner JF, Sallman DA, R\u00e9cher C, Daver NG, Leung AYH, Hiwase DK, et al. Magrolimab plus azacitidine vs physician\u2019s choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study. Blood. 2025;146(5):590\u2013600.","journal-title":"Blood"},{"issue":"16","key":"1775_CR32","doi-asserted-by":"publisher","first-page":"1525110","DOI":"10.3389\/fimmu.2025.1525110","volume":"26","author":"Q Liu","year":"2025","unstructured":"Liu Q, Yang J, Lv L, Zhang X, Li M, Xu L, et al. Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia. Front Immunol. 2025;26(16):1525110.","journal-title":"Front Immunol"},{"issue":"10","key":"1775_CR33","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106\u201317.","journal-title":"Cancer Discov"},{"issue":"15","key":"1775_CR34","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.18.01600","volume":"37","author":"AH Wei","year":"2019","unstructured":"Wei AH, Strickland SA, Hou JZ, Fiedler W, Lin TL, Walter RB, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study. J Clin Oncol. 2019;37(15):1277\u201384.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1775_CR35","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3324\/haematol.2009.009217","volume":"94","author":"EW Schaefer","year":"2009","unstructured":"Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF, Roy V, Slack J, et al. A phase 2 study of vorinostat in acute myeloid leukemia. Haematol. 2009;94(10):1375\u201382.","journal-title":"Haematol"},{"issue":"10","key":"1775_CR36","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.3324\/haematol.2015.129577","volume":"100","author":"EM Ocio","year":"2015","unstructured":"Ocio EM, Herrera P, Olave MT, Castro N, P\u00e9rez-Sim\u00f3n JA, Brunet S, et al. Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib\/II panobidara study. Haematologica. 2015;100(10):1294\u2013300.","journal-title":"Haematologica"},{"issue":"1","key":"1775_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.68","volume":"4","author":"P Tan","year":"2014","unstructured":"Tan P, Wei A, Mithraprabhu S, Cummings N, Liu HB, Perugini M, et al. Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Cancer J. 2014;4(1):e170.","journal-title":"Blood Cancer J"},{"issue":"140","key":"1775_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107480","volume":"1","author":"G Garcia-Manero","year":"2024","unstructured":"Garcia-Manero G, Kazmierczak M, Wierzbowska A, Fong CY, Keng MK, Ballinari G, et al. Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: primula phase III study. Leuk Res. 2024;1(140):107480.","journal-title":"Leuk Res"},{"issue":"2","key":"1775_CR39","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","volume":"33","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33(2):379\u201389.","journal-title":"Leukemia"},{"issue":"5","key":"1775_CR40","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00277-021-04465-4","volume":"100","author":"M Heuser","year":"2021","unstructured":"Heuser M, Smith BD, Fiedler W, Sekeres MA, Montesinos P, Leber B, et al. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. Ann Hematol. 2021;100(5):1181\u201394.","journal-title":"Ann Hematol"},{"issue":"4","key":"1775_CR41","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/bjh.13323","volume":"169","author":"RT Swords","year":"2015","unstructured":"Swords RT, Erba HP, DeAngelo DJ, Bixby DL, Altman JK, Maris M, et al. Pevonedistat (MLN4924), a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: A phase 1 study. Br J Haematol. 2015;169(4):534\u201343.","journal-title":"Br J Haematol"},{"issue":"7","key":"1775_CR42","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1038\/s41375-021-01125-4","volume":"35","author":"MA Sekeres","year":"2021","unstructured":"Sekeres MA, Watts J, Radinoff A, Sangerman MA, Cerrano M, Lopez PF, et al. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS\/CMML or low-blast AML. Leukemia. 2021;35(7):2119\u201324.","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"1775_CR43","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1182\/blood-2021-146154","volume":"138","author":"MA Sekeres","year":"2021","unstructured":"Sekeres MA, Girshova L, Doronin VA, Diez-Campelo M, Valcarcel D, Kambhampati S, et al. Pevonedistat (PEV) + azacitidine (AZA) versus AZA alone as first-line treatment for patients with higher-risk myelodysplastic syndromes (MDS)\/chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML) with 20\u201330% marrow blasts: the randomized phase 3 panther trial (NCT03268954). Blood. 2021;138(Supplement 1):242.","journal-title":"Blood"},{"issue":"1","key":"1775_CR44","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s00280-024-04742-9","volume":"95","author":"KR Maher","year":"2025","unstructured":"Maher KR, Shafer D, Schaar D, Bandyopadhyay D, Deng X, Wright J, et al. A phase I study of MLN4924 and belinostat in relapsed\/refractory acute myeloid leukemia or myelodysplastic syndrome. Cancer Chemother Pharmacol. 2025;95(1):24.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"1775_CR45","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1080\/10428194.2024.2431878","volume":"66","author":"NJ Short","year":"2025","unstructured":"Short NJ, Wierzbowska A, Cluzeau T, Laribi K, Recher C, Czyz J, et al. Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia. Leuk Lymphoma. 2025;66(3):458\u201368.","journal-title":"Leuk Lymphoma"},{"key":"1775_CR46","unstructured":"City of Hope Medical Center. A Phase I Study of Pevonedistat (TAK-924) and Decitabine Combination Therapy in High Risk Acute Myeloid Leukemia [Internet]. clinicaltrials.gov. 2025 Jan [cited 2025 Mar 24]. Report No: NCT03009240. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03009240."},{"key":"1775_CR47","unstructured":"Watts J. An Open-Label, Dose Escalation, Phase 1 Study of PEVONEDISTAT, a Novel Inhibitor of the NEDD8-Activating Enzyme (NAE), in Combination With Low Dose Cytarabine (LDAC) in Adult Patients With Acute Myelogenous Leukemia (AML) and Advanced Myelodysplastic Syndromes (MDS) [Internet]. clinicaltrials.gov. 2021 Dec [cited 2025 Mar 24]. Report No: NCT03459859. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03459859."},{"key":"1775_CR48","unstructured":"National Cancer Institute (NCI). A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome [Internet]. clinicaltrials.gov. 2024 Jan [cited 2025 Mar 25]. Report No: NCT03813147. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03813147."},{"issue":"2","key":"1775_CR49","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/leu.2017.213","volume":"32","author":"C Meyer","year":"2018","unstructured":"Meyer C, Burmeister T, Gr\u00f6ger D, Tsaur G, Fechina L, Renneville A, et al. The MLL recombinome of acute leukemias in 2017. Leukemia. 2018;32(2):273\u201384.","journal-title":"Leukemia"},{"issue":"138","key":"1775_CR50","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1182\/blood-2021-146944","volume":"23","author":"EM Stein","year":"2021","unstructured":"Stein EM, Aldoss I, DiPersio JF, Stone RM, Arellano ML, Rosen G, et al. Safety and efficacy of menin inhibition in patients (Pts) with MLL-rearranged and NPM1 mutant acute leukemia: A phase (Ph) 1, first-in-human study of SNDX-5613 (augment 101). Blood. 2021;23(138):699.","journal-title":"Blood"},{"issue":"144","key":"1775_CR51","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1182\/blood-2024-204375","volume":"5","author":"GC Issa","year":"2024","unstructured":"Issa GC, Cuglievan B, Daver N, DiNardo CD, Farhat A, Short NJ, et al. Phase I\/II Study of the all-oral combination of revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (save) in R\/R AML. Blood. 2024;5(144):216.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1775_CR52","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1182\/blood-2023-190475","volume":"142","author":"AD Goldberg","year":"2023","unstructured":"Goldberg AD, Corum D, Ahsan J, Nie K, Kozlek T, Leoni M, et al. Komet-008: A phase 1 study to determine the safety and tolerability of ziftomenib combinations for the treatment of KMT2A-rearranged or NPM1-Mutant relapsed\/refractory acute myeloid leukemia. Blood. 2023;142(Supplement 1):1553.","journal-title":"Blood"},{"issue":"18","key":"1775_CR53","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1200\/JCO.2005.09.133","volume":"23","author":"EJ Feldman","year":"2005","unstructured":"Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O\u2019Connor J, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005;23(18):4110\u20136.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1775_CR54","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41375-020-0773-5","volume":"35","author":"P Montesinos","year":"2021","unstructured":"Montesinos P, Roboz GJ, Bulabois CE, Subklewe M, Platzbecker U, Ofran Y, et al. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2\/3 study. Leukemia. 2021;35(1):62\u201374.","journal-title":"Leukemia"},{"issue":"6","key":"1775_CR55","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1182\/blood.2020007732","volume":"137","author":"GL Uy","year":"2021","unstructured":"Uy GL, Aldoss I, Foster MC, Sayre PH, Wieduwilt MJ, Advani AS, et al. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2021;137(6):751\u201362.","journal-title":"Blood"},{"issue":"4","key":"1775_CR56","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1038\/s41375-019-0645-z","volume":"34","author":"AS Kubasch","year":"2020","unstructured":"Kubasch AS, Schulze F, Giagounidis A, G\u00f6tze KS, Kr\u00f6nke J, Sockel K, et al. Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. Leukemia. 2020;34(4):1182\u20136.","journal-title":"Leukemia"},{"issue":"11","key":"1775_CR57","doi-asserted-by":"publisher","first-page":"e902","DOI":"10.1016\/S2352-3026(23)00207-7","volume":"10","author":"T Pabst","year":"2023","unstructured":"Pabst T, Papayannidis C, Demirkan F, Doronin V, Fogliatto LM, Guttke C, et al. Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study. Lancet Haematol. 2023;10(11):e902\u201312.","journal-title":"Lancet Haematol"},{"issue":"9","key":"1775_CR58","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/10428194.2024.2346755","volume":"65","author":"F Ravandi","year":"2024","unstructured":"Ravandi F, Subklewe M, Walter RB, Vachhani P, Ossenkoppele G, Buecklein V, et al. Safety and tolerability of AMG 330 in adults with relapsed\/refractory AML: A phase 1a dose-escalation study. Leuk Lymphoma. 2024;65(9):1281\u201391.","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"1775_CR59","doi-asserted-by":"publisher","first-page":"6492","DOI":"10.1182\/bloodadvances.2023010956","volume":"7","author":"F Ravandi","year":"2023","unstructured":"Ravandi F, Bashey A, Foran J, Stock W, Mawad R, Short N, et al. Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed\/refractory acute myeloid leukemia. Blood Adv. 2023;7(21):6492\u2013505.","journal-title":"Blood Adv"},{"issue":"9","key":"1775_CR60","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","volume":"15","author":"RK Hills","year":"2014","unstructured":"Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986\u201396.","journal-title":"Lancet Oncol"},{"issue":"12","key":"1775_CR61","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.clml.2020.07.001","volume":"20","author":"A Genthon","year":"2020","unstructured":"Genthon A, Brissot E, Malard F, van de Wyngaert Z, Bonnin A, Banet A, et al. Gemtuzumab ozogamicin combined with intensive chemotherapy in patients with acute myeloid leukemia relapsing after allogenic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2020;20(12):791\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"28","key":"1775_CR62","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1200\/JCO.20.03048","volume":"39","author":"JA Pollard","year":"2021","unstructured":"Pollard JA, Guest E, Alonzo TA, Gerbing RB, Loken MR, Brodersen LE, et al. Gemtuzumab ozogamicin Improves event-free survival and reduces relapse in pediatric KMT2A-rearranged AML: results from the phase III children\u2019s oncology group trial AAML0531. J Clin Oncol Off J Am Soc Clin Oncol. 2021;39(28):3149\u201360.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1775_CR63","unstructured":"M.D. Anderson Cancer Center. A Pilot Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Gemtuzumab Ozogamicin (GO) in Relapsed Refractory Patients With Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS) [Internet]. clinicaltrials.gov. 2025 Apr [cited 2025 Aug 20]. Report No: NCT03672539. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03672539."},{"issue":"4","key":"1775_CR64","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1080\/10428194.2024.2438809","volume":"66","author":"C Oliai","year":"2025","unstructured":"Oliai C, Park S, Damon LE, Jonas BA, Jeyakumar D, Wieduwilt MJ, et al. CPX-351 plus gemtuzumab ozogamicin for relapsed\/refractory acute myelogenous leukemia: A university of California hematologic malignancies consortium trial. Leuk Lymphoma. 2025;66(4):773\u20139.","journal-title":"Leuk Lymphoma"},{"key":"1775_CR65","unstructured":"Technische Universit\u00e4t Dresden. MidOStaurin + Gemtuzumab OzogAmIcin Combination in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) [Internet]. clinicaltrials.gov. 2023 Aug [cited 2025 Aug 20]. Report No: NCT04385290. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04385290."},{"key":"1775_CR66","unstructured":"Quigley J. Phase Ib Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 [Internet]. clinicaltrials.gov. 2025 Apr [cited 2025 Aug 20]. Report No: NCT04070768. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04070768."},{"key":"1775_CR67","unstructured":"Pyzer AR, Dillon LW, Sharon E, Karrison TG, Zha Y, Fulton N, et al. Randomized Phase II Study to Assess the Role of Single-Agent Nivolumab to Maintain Remission in Acute Myeloid Leukemia. Blood Adv. bloodadvances.2024015176. 2025."},{"issue":"Supplement_1","key":"1775_CR68","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1182\/blood-2019-131494","volume":"134","author":"NG Daver","year":"2019","unstructured":"Daver NG, Garcia-Manero G, Konopleva MY, Alfayez M, Pemmaraju N, Kadia TM, et al. Azacitidine (AZA) with nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in relapsed\/refractory acute myeloid leukemia: A non-randomized, prospective, phase 2 study. Blood. 2019;134(Supplement_1):830.","journal-title":"Blood"},{"issue":"3","key":"1775_CR69","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3390\/cancers16030496","volume":"16","author":"A Verma","year":"2024","unstructured":"Verma A, Chi YY, Malvar J, Lamble A, Chaudhury S, Agarwal A, et al. Nivolumab Plus 5-azacitidine in pediatric relapsed\/refractory acute myeloid leukemia (AML): phase I\/II trial results from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. Cancers. 2024;16(3):496.","journal-title":"Cancers"},{"issue":"1","key":"1775_CR70","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003392","volume":"10","author":"M Goswami","year":"2022","unstructured":"Goswami M, Gui G, Dillon LW, Lindblad KE, Thompson J, Valdez J, et al. Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia. J Immunother Cancer. 2022;10(1):e003392.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1775_CR71","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00277-023-05552-4","volume":"103","author":"JP Bewersdorf","year":"2024","unstructured":"Bewersdorf JP, Shallis RM, Sharon E, Park S, Ramaswamy R, Roe CE, et al. A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes\/neoplasms or acute myeloid leukemia refractory to hypomethylating agents. Ann Hematol. 2024;103(1):105\u201316.","journal-title":"Ann Hematol"},{"issue":"7","key":"1775_CR72","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1182\/bloodadvances.2021006138","volume":"6","author":"AM Zeidan","year":"2022","unstructured":"Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, et al. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. Blood Adv. 2022;6(7):2219\u201329.","journal-title":"Blood Adv"},{"issue":"20","key":"1775_CR73","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.1002\/cncr.33690","volume":"127","author":"K Saxena","year":"2021","unstructured":"Saxena K, Herbrich SM, Pemmaraju N, Kadia TM, DiNardo CD, Borthakur G, et al. A phase 1b\/2 study of azacitidine with PD-L1 antibody avelumab in relapsed\/refractory acute myeloid leukemia. Cancer. 2021;127(20):3761\u201371.","journal-title":"Cancer"},{"issue":"2","key":"1775_CR74","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1056\/NEJMoa1601202","volume":"375","author":"MS Davids","year":"2016","unstructured":"Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med. 2016;375(2):143\u201353.","journal-title":"N Engl J Med"},{"issue":"2","key":"1775_CR75","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41375-024-02457-7","volume":"39","author":"IM Bouligny","year":"2025","unstructured":"Bouligny IM, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Alvarado Y, et al. A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms. Leukemia. 2025;39(2):524\u20138.","journal-title":"Leukemia"},{"issue":"3","key":"1775_CR76","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00277-021-04734-2","volume":"101","author":"AM Zeidan","year":"2022","unstructured":"Zeidan AM, DeAngelo DJ, Palmer J, Seet CS, Tallman MS, Wei X, et al. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed\/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. Ann Hematol. 2022;101(3):557\u201369.","journal-title":"Ann Hematol"},{"issue":"3","key":"1775_CR77","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/bloodadvances.2017014175","volume":"2","author":"PG Maslak","year":"2018","unstructured":"Maslak PG, Dao T, Bernal Y, Chanel SM, Zhang R, Frattini M, et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv. 2018;2(3):224\u201334.","journal-title":"Blood Adv"},{"key":"1775_CR78","unstructured":"Sellas Life Sciences Group. A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator27;s Choice of Best Available Therapy in Subjects With Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy [Internet]. clinicaltrials.gov. 2024 Apr [cited 2025 Apr 2]. Report No: NCT04229979. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04229979."},{"issue":"368","key":"1775_CR79","doi-asserted-by":"publisher","first-page":"368r171","DOI":"10.1126\/scitranslmed.aag1298","volume":"8","author":"J Rosenblatt","year":"2016","unstructured":"Rosenblatt J, Stone RM, Uhl L, Neuberg D, Joyce R, Levine JD, et al. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci Transl Med. 2016;8(368):368r171.","journal-title":"Sci Transl Med"},{"issue":"10","key":"1775_CR80","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1080\/21645515.2021.1943991","volume":"17","author":"P Chevallier","year":"2021","unstructured":"Chevallier P, Saiagh S, Dehame V, Guillaume T, Peterlin P, Bercegeay S, et al. A phase I\/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients. Hum Vaccines Immunother. 2021;17(10):3511\u20134.","journal-title":"Hum Vaccines Immunother"},{"issue":"2","key":"1775_CR81","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/jca.10080","volume":"19","author":"JJ Lee","year":"2004","unstructured":"Lee JJ, Kook H, Park MS, Nam JH, Choi BH, Song WH, et al. Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation. J Clin Apher. 2004;19(2):66\u201370.","journal-title":"J Clin Apher"},{"issue":"15","key":"1775_CR82","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood-2017-04-780155","volume":"130","author":"S Anguille","year":"2017","unstructured":"Anguille S, Van de Velde AL, Smits EL, Van Tendeloo VF, Juliusson G, Cools N, et al. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. Blood. 2017;130(15):1713\u201321.","journal-title":"Blood"},{"issue":"10","key":"1775_CR83","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s00262-018-2198-9","volume":"67","author":"AA van de Loosdrecht","year":"2018","unstructured":"van de Loosdrecht AA, van Wetering S, Santegoets SJAM, Singh SK, Eeltink CM, den Hartog Y, et al. A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia. Cancer Immunol Immunother. 2018;67(10):1505\u201318.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"1775_CR84","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/MPH.0b013e3182a8f58f","volume":"36","author":"EA Raetz","year":"2014","unstructured":"Raetz EA, Morrison D, Romanos-Sirakis E, Gaynon P, Sposto R, Bhojwani D, et al. A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (all): A report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. J Pediatr Hematol Oncol. 2014;36(6):458\u201363.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"19","key":"1775_CR85","doi-asserted-by":"publisher","first-page":"13336","DOI":"10.1039\/D4RA01925C","volume":"14","author":"Y Li","year":"2024","unstructured":"Li Y, Chen S, Rahimizadeh K, Zhang Z, Veedu RN. Inhibition of survivin by 2\u2032-O-methyl phosphorothioate-modified steric-blocking antisense oligonucleotides. RSC Adv. 2024;14(19):13336\u201341.","journal-title":"RSC Adv"},{"issue":"3","key":"1775_CR86","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1089\/108729002760220798","volume":"12","author":"RJ Klasa","year":"2002","unstructured":"Klasa RJ, Gillum AM, Klem RE, Frankel SR. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 2002;12(3):193\u2013213.","journal-title":"Antisense Nucleic Acid Drug Dev"},{"issue":"27","key":"1775_CR87","doi-asserted-by":"publisher","first-page":"42374","DOI":"10.18632\/oncotarget.9872","volume":"7","author":"AS Ebrahim","year":"2016","unstructured":"Ebrahim AS, Kandouz M, Liddane A, Sabbagh H, Hou Y, Li C, et al. PNT2258, a novel deoxyribonucleic acid inhibitor, induces cell cycle arrest and apoptosis via a distinct mechanism of action: a new class of drug for non-Hodgkin\u2019s lymphoma. Oncotarget. 2016;7(27):42374\u201384.","journal-title":"Oncotarget"},{"issue":"12","key":"1775_CR88","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.clml.2021.07.016","volume":"21","author":"W Harb","year":"2021","unstructured":"Harb W, Lakhani NJ, Messmann R, Klencke B, Al-Katib AM. A phase 2 study of PNT2258 for treatment of relapsed or refractory B-cell malignancies. Clin Lymphoma Myeloma Leuk. 2021;21(12):823\u201330.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"1775_CR89","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.3109\/10428194.2016.1146947","volume":"57","author":"MH Kirschbaum","year":"2016","unstructured":"Kirschbaum MH, Frankel P, Synold TW, Xie Z, Yen Y, Popplewell L, et al. A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: A California Cancer Consortium study. Leuk Lymphoma. 2016;57(10):2307\u201314.","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"1775_CR90","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1158\/1078-0432.CCR-08-0109","volume":"14","author":"RB Klisovic","year":"2008","unstructured":"Klisovic RB, Blum W, Wei X, Liu S, Liu Z, Xie Z, et al. Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14(12):3889\u201395.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"314","key":"1775_CR91","doi-asserted-by":"publisher","first-page":"314ra185","DOI":"10.1126\/scitranslmed.aac5272","volume":"7","author":"D Hong","year":"2015","unstructured":"Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med. 2015;7(314):314ra185.","journal-title":"Sci Transl Med"},{"issue":"17","key":"1775_CR92","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1158\/1078-0432.CCR-22-2483","volume":"29","author":"M Roschewski","year":"2023","unstructured":"Roschewski M, Patel MR, Reagan PM, Saba NS, Collins GP, Arkenau HT, et al. Phase I study of acalabrutinib plus danvatirsen (AZD9150) in relapsed\/refractory diffuse large b-cell lymphoma including circulating tumor DNA biomarker assessment. Clin Cancer Res. 2023;29(17):3301\u201312.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1775_CR93","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3109\/10428194.2011.610012","volume":"53","author":"MC Lanasa","year":"2012","unstructured":"Lanasa MC, Davis PH, Datto M, Li Z, Gockerman JP, Moore JO, et al. Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53(2):218\u201324.","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"1775_CR94","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1182\/bloodadvances.2022008378","volume":"7","author":"CD DiNardo","year":"2022","unstructured":"DiNardo CD, Venugopal S, Lachowiez C, Takahashi K, Loghavi S, Montalban-Bravo G, et al. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv. 2022;7(11):2378\u201387.","journal-title":"Blood Adv"},{"issue":"14","key":"1775_CR95","doi-asserted-by":"publisher","first-page":"7916","DOI":"10.3390\/ijms25147916","volume":"25","author":"A Kowalczyk","year":"2024","unstructured":"Kowalczyk A, Zarychta J, Lejman M, Latoch E, Zawitkowska J. Clinical Implications of isocitrate dehydrogenase mutations and targeted treatment of acute myeloid leukemia with mutant isocitrate dehydrogenase inhibitors-recent advances, challenges and future prospects. Int J Mol Sci. 2024;25(14):7916.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1775_CR96","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1182\/bloodadvances.2020001503","volume":"4","author":"S Choe","year":"2020","unstructured":"Choe S, Wang H, DiNardo CD, Stein EM, de Botton S, Roboz GJ, et al. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. Blood Adv. 2020;4(9):1894\u2013905.","journal-title":"Blood Adv"},{"issue":"6","key":"1775_CR97","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3316","volume":"42","author":"J Yang","year":"2024","unstructured":"Yang J, Wang Z, Wu K, Nie B, Li L, Ruan J, et al. Isocitrate dehydrogenase 2 mutation promotes cytarabine resistance in acute myeloid leukemia by Warburg effect. Hematol Oncol. 2024;42(6):e3316.","journal-title":"Hematol Oncol"},{"issue":"3","key":"1775_CR98","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41375-021-01468-y","volume":"36","author":"S Cathelin","year":"2022","unstructured":"Cathelin S, Sharon D, Subedi A, Cojocari D, Phillips DC, Leverson JD, et al. Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia. Leukemia. 2022;36(3):869\u201372.","journal-title":"Leukemia"},{"issue":"1","key":"1775_CR99","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1158\/1078-0432.CCR-24-2196","volume":"31","author":"AC Woods","year":"2025","unstructured":"Woods AC, Norsworthy KJ, Choe M, Gehrke BJ, Chen H, Vallejo J, et al. FDA approval summary: olutasidenib for adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 1 mutation. Clin Cancer Res Off J Am Assoc Cancer Res. 2025;31(1):12\u20137.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"11","key":"1775_CR100","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1080\/17474086.2024.2422554","volume":"17","author":"M Norman","year":"2024","unstructured":"Norman M, Yamartino K, Gerstein R, Shallis R, Mendez L, Podoltsev N, et al. A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS. Expert Rev Hematol. 2024;17(11):755\u201367.","journal-title":"Expert Rev Hematol"},{"issue":"7","key":"1775_CR101","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jgg.2020.04.006","volume":"47","author":"NM Hoang","year":"2020","unstructured":"Hoang NM, Rui L. DNA methyltransferases in hematological malignancies. J Genet Genomics Yi Chuan Xue Bao. 2020;47(7):361\u201372.","journal-title":"J Genet Genomics Yi Chuan Xue Bao"},{"issue":"4","key":"1775_CR102","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1177\/10781552241238979","volume":"30","author":"R Haumschild","year":"2024","unstructured":"Haumschild R, Kennerly-Shah J, Barbarotta L, Zeidan AM. Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes\/neoplasms and acute myeloid leukemia: a multidisciplinary review. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract. 2024;30(4):721\u201336.","journal-title":"J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract"},{"issue":"1","key":"1775_CR103","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/2162-3619-3-10","volume":"3","author":"BD Smith","year":"2014","unstructured":"Smith BD, Beach CL, Mahmoud D, Weber L, Henk HJ. Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: A real-world, retrospective, claims-based, comparative analysis. Exp Hematol Oncol. 2014;3(1):10.","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"1775_CR104","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1177\/2040620712464882","volume":"3","author":"C Khan","year":"2012","unstructured":"Khan C, Pathe N, Fazal S, Lister J, Rossetti JM. Azacitidine in the management of patients with myelodysplastic syndromes. Ther Adv Hematol. 2012;3(6):355\u201373.","journal-title":"Ther Adv Hematol"},{"issue":"3","key":"1775_CR105","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223\u201332.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1775_CR106","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291\u20139.","journal-title":"Blood"},{"issue":"10","key":"1775_CR107","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1182\/bloodadvances.2020001779","volume":"4","author":"AM Zeidan","year":"2020","unstructured":"Zeidan AM, Wang R, Wang X, Shallis RM, Podoltsev NA, Bewersdorf JP, et al. Clinical outcomes of older patients with AML receiving hypomethylating agents: A large population-based study in the United States. Blood Adv. 2020;4(10):2192\u2013201.","journal-title":"Blood Adv"},{"issue":"15","key":"1775_CR108","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1182\/blood.2022016293","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Roboz GJ, Montesinos P, Thol FR, Ravandi F, et al. Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine. Blood. 2022;140(15):1674\u201385.","journal-title":"Blood"},{"issue":"26","key":"1775_CR109","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","volume":"383","author":"AH Wei","year":"2020","unstructured":"Wei AH, D\u00f6hner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med. 2020;383(26):2526\u201337.","journal-title":"N Engl J Med"},{"issue":"4","key":"1775_CR110","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, D\u00f6hner H, et al. Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99(4):615\u201324.","journal-title":"Am J Hematol"},{"key":"1775_CR111","unstructured":"Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS) | Aprea Therapeutics [Internet]. [cited 2025 Oct 21]. Available from: https:\/\/ir.aprea.com\/news-releases\/news-release-details\/aprea-therapeutics-announces-results-primary-endpoint-phase-3\/."},{"issue":"20","key":"1775_CR112","first-page":"6565","volume":"50","author":"JC Reed","year":"1990","unstructured":"Reed JC, Stein C, Subasinghe C, Haldar S, Croce CM, Yum S, et al. Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res. 1990;50(20):6565\u201370.","journal-title":"Cancer Res"},{"issue":"1","key":"1775_CR113","first-page":"97","volume":"14","author":"M Gagliardi","year":"2022","unstructured":"Gagliardi M, Ashizawa AT. Making sense of antisense oligonucleotide therapeutics targeting Bcl-2. Pharm. 2022;14(1):97.","journal-title":"Pharm"},{"issue":"2","key":"1775_CR114","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1089\/ard.1994.4.71","volume":"4","author":"S Kitada","year":"1994","unstructured":"Kitada S, Takayama S, De Riel K, Tanaka S, Reed JC. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev. 1994;4(2):71\u20139.","journal-title":"Antisense Res Dev"},{"issue":"3","key":"1775_CR115","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2174\/157488706778250050","volume":"1","author":"JN Moreira","year":"2006","unstructured":"Moreira JN, Santos A, Sim\u00f5es S. Bcl-2-targeted antisense therapy (oblimersen sodium): towards clinical reality. Rev Recent Clin Trials. 2006;1(3):217\u201335.","journal-title":"Rev Recent Clin Trials"},{"issue":"6","key":"1775_CR116","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/01.cco.0000142074.67968.eb","volume":"16","author":"A Chanan-Khan","year":"2004","unstructured":"Chanan-Khan A. Bcl-2 antisense therapy in hematologic malignancies. Curr Opin Oncol. 2004;16(6):581\u20135.","journal-title":"Curr Opin Oncol"},{"key":"1775_CR117","unstructured":"Xy L, HZ, Dm H. [Bcl-2 antisense oligodeoxynucleotide enhances araninosyl cytosine-induced apoptosis of primary leukemia cells]. Ai Zheng Aizheng Chin J Cancer [Internet]. 2002 Dec [cited 2024 Jan 8]: [21(12)]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/12520735\/."},{"issue":"1","key":"1775_CR118","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0167-4781(99)00142-6","volume":"1489","author":"N Agarwal","year":"1999","unstructured":"Agarwal N, Gewirtz AM. Oligonucleotide therapeutics for hematologic disorders. Biochim Biophys Acta BBA - Gene Struct Expr. 1999;1489(1):85\u201396.","journal-title":"Biochim Biophys Acta BBA - Gene Struct Expr"},{"issue":"6","key":"1775_CR119","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000914","volume":"7","author":"S Turkalj","year":"2023","unstructured":"Turkalj S, Radtke FA, Vyas P. An overview of targeted therapies in acute myeloid leukemia. HemaSphere. 2023;7(6):e914.","journal-title":"HemaSphere"},{"issue":"1","key":"1775_CR120","doi-asserted-by":"publisher","first-page":"2338509","DOI":"10.1080\/16078454.2024.2338509","volume":"29","author":"X Wang","year":"2024","unstructured":"Wang X, Xiao Z, Qin T, Xu Z, Jia Y, Qu S, et al. Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with DDX41 mutations. Hematol. 2024;29(1):2338509.","journal-title":"Hematol"},{"issue":"14","key":"1775_CR121","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71037","volume":"14","author":"Y Cai","year":"2025","unstructured":"Cai Y, Rui J, Ding Z, Xie J, Jin Z, Xiao J, et al. Better response and prognosis of venetoclax plus hypomethylating agents over intensive chemotherapy in young adults with newly diagnosed ASXL1 -mutated acute myeloid leukemia. Cancer Med. 2025;14(14):e71037.","journal-title":"Cancer Med"},{"issue":"19","key":"1775_CR122","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1182\/blood.2023020649","volume":"142","author":"J Senapati","year":"2023","unstructured":"Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, et al. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood. 2023;142(19):1647\u201357.","journal-title":"Blood"},{"issue":"11","key":"1775_CR123","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135(11):791\u2013803.","journal-title":"Blood"},{"issue":"12","key":"1775_CR124","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","volume":"8","author":"HE Ramsey","year":"2018","unstructured":"Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, et al. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 2018;8(12):1566\u201381.","journal-title":"Cancer Discov"},{"key":"1775_CR125","doi-asserted-by":"publisher","unstructured":"Wei Y, Cao Y, Sun R, Cheng L, Xiong X, Jin X, et al. Targeting Bcl-2 Proteins in Acute Myeloid Leukemia. Front Oncol [Internet]. 2020 Nov 5 [cited 2025 Aug 18]: [10 p.]. Available from: https:\/\/www.frontiersin.org\/journals\/oncology\/articles\/https:\/\/doi.org\/10.3389\/fonc.2020.584974\/full.","DOI":"10.3389\/fonc.2020.584974\/full"},{"issue":"3","key":"1775_CR126","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/bjh.18887","volume":"202","author":"C Sartor","year":"2023","unstructured":"Sartor C, Brunetti L, Audisio E, Cignetti A, Zannoni L, Cristiano G, et al. A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure. Br J Haematol. 2023;202(3):599\u2013607.","journal-title":"Br J Haematol"},{"key":"1775_CR127","doi-asserted-by":"publisher","DOI":"10.1177\/20406207241311776","volume":"16","author":"X Xu","year":"2025","unstructured":"Xu X, Liu R, Chen H, Yang R, Gao G, He A, et al. Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia. Ther Adv Hematol. 2025;16:20406207241311776.","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"1775_CR128","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1186\/s40001-024-02108-8","volume":"29","author":"MS Hosseini","year":"2024","unstructured":"Hosseini MS, Sanaat Z, Akbarzadeh MA, Vaez-Gharamaleki Y, Akbarzadeh M. Histone deacetylase inhibitors for leukemia treatment: current status and future directions. Eur J Med Res. 2024;29(1):514.","journal-title":"Eur J Med Res"},{"issue":"6","key":"1775_CR129","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/j.ejmech.2010.02.030","volume":"45","author":"P Bertrand","year":"2010","unstructured":"Bertrand P. Inside HDAC with HDAC inhibitors. Eur J Med Chem. 2010;45(6):2095\u2013116.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"1775_CR130","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/cancers14010087","volume":"14","author":"A Sochacka-\u0106wik\u0142a","year":"2021","unstructured":"Sochacka-\u0106wik\u0142a A, M\u0105czy\u0144ski M. Regiec A. lymphoid leukemia. Cancers. 2021;14(1):87.","journal-title":"Cancers"},{"issue":"3","key":"1775_CR131","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.leukres.2014.12.014","volume":"39","author":"FF Corrales-Medina","year":"2015","unstructured":"Corrales-Medina FF, Manton CA, Orlowski RZ, Chandra J. Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models. Leuk Res. 2015;39(3):371\u20139.","journal-title":"Leuk Res"},{"issue":"10","key":"1775_CR132","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","volume":"12","author":"BS Mann","year":"2007","unstructured":"Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncol. 2007;12(10):1247\u201352.","journal-title":"Oncol"},{"issue":"11","key":"1775_CR133","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.3390\/cancers11111794","volume":"11","author":"E San Jos\u00e9-En\u00e9riz","year":"2019","unstructured":"San Jos\u00e9-En\u00e9riz E, Gimenez-Camino N, Agirre X, Prosper F. HDAC inhibitors in acute myeloid leukemia. Cancers. 2019;11(11):1794.","journal-title":"Cancers"},{"issue":"Spec Feature","key":"1775_CR134","first-page":"84","volume":"9","author":"LA Raedler","year":"2016","unstructured":"Raedler LA. Farydak (panobinostat) First HDAC inhibitor approved for patients with relapsed multiple myeloma. Am Health Drug Benefits. 2016;9(Spec Feature):84\u20137.","journal-title":"Am Health Drug Benefits"},{"issue":"4","key":"1775_CR135","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3390\/cells14040269","volume":"14","author":"M Sicurella","year":"2025","unstructured":"Sicurella M, De Chiara M, Neri LM. Hedgehog and PI3K\/Akt\/mTOR signaling pathways involvement in leukemic malignancies: crosstalk and role in cell death. Cells. 2025;14(4):269.","journal-title":"Cells"},{"key":"1775_CR136","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.944760","volume":"10","author":"S Tesanovic","year":"2022","unstructured":"Tesanovic S, Krenn PW, Aberger F. Hedgehog\/GLI signaling in hematopoietic development and acute myeloid leukemia-from bench to bedside. Front Cell Dev Biol. 2022;10:944760.","journal-title":"Front Cell Dev Biol"},{"issue":"20","key":"1775_CR137","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1158\/1078-0432.CCR-19-0365","volume":"25","author":"KJ Norsworthy","year":"2019","unstructured":"Norsworthy KJ, By K, Subramaniam S, Zhuang L, Del Valle PL, Przepiorka D, et al. FDA approval summary: glasdegib for newly diagnosed acute myeloid leukemia. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25(20):6021\u20135.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"10","key":"1775_CR138","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1038\/s41375-023-02001-z","volume":"37","author":"MA Sekeres","year":"2023","unstructured":"Sekeres MA, Montesinos P, Novak J, Wang J, Jeyakumar D, Tomlinson B, et al. Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial. Leukemia. 2023;37(10):2017\u201326.","journal-title":"Leukemia"},{"issue":"3","key":"1775_CR139","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/bjh.13426","volume":"170","author":"AA Khan","year":"2015","unstructured":"Khan AA, Harrison CN, McLornan DP. Targeting of the Hedgehog pathway in myeloid malignancies: still a worthy chase? Br J Haematol. 2015;170(3):323\u201335.","journal-title":"Br J Haematol"},{"key":"1775_CR140","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221112899","volume":"13","author":"A Snow","year":"2022","unstructured":"Snow A, Zeidner JF. The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype? Ther Adv Hematol. 2022;13:20406207221112899.","journal-title":"Ther Adv Hematol"},{"key":"1775_CR141","doi-asserted-by":"publisher","unstructured":"Perner F, Gadrey JY, Armstrong SA, K\u00fchn MWM. Targeting the Menin\u2013KMT2A interaction in leukemia: Lessons learned and future directions. Int J Cancer [Internet]. [cited 2025 Mar 25]. n\/a(n\/a). Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1002\/ijc.35332.","DOI":"10.1002\/ijc.35332"},{"issue":"2","key":"1775_CR142","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","volume":"123","author":"A Yokoyama","year":"2005","unstructured":"Yokoyama A, Somervaille TCP, Smith KS, Rozenblatt-Rosen O, Meyerson M, Cleary ML. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell. 2005;123(2):207\u201318.","journal-title":"Cell"},{"key":"1775_CR143","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02161-5","author":"YY Syed","year":"2025","unstructured":"Syed YY. Revumenib: first approval. Drugs. 2025. https:\/\/doi.org\/10.1007\/s40265-025-02161-5.","journal-title":"Drugs"},{"issue":"7954","key":"1775_CR144","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nat. 2023;615(7954):920\u20134.","journal-title":"Nat"},{"issue":"10","key":"1775_CR145","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.3324\/haematol.2022.282160","volume":"108","author":"J Rausch","year":"2023","unstructured":"Rausch J, Dzama MM, Dolgikh N, Stiller HL, Bohl SR, Lahrmann C, et al. Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax. Haematol. 2023;108(10):2837\u201343.","journal-title":"Haematol"},{"issue":"136","key":"1775_CR146","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2020-134942","volume":"5","author":"ES Wang","year":"2020","unstructured":"Wang ES, Altman JK, Pettit K, De Botton S, Walter RP, Fenaux P, et al. Preliminary data on a phase 1\/2A first in human study of the menin-KMT2A (MLL) inhibitor KO-539 in patients with relapsed or refractory acute myeloid leukemia. Blood. 2020;5(136):7\u20138.","journal-title":"Blood"},{"issue":"2","key":"1775_CR147","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/hematolrep16020024","volume":"16","author":"A Candoni","year":"2024","unstructured":"Candoni A, Coppola G. A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia. Hematol Rep. 2024;16(2):244\u201354.","journal-title":"Hematol Rep"},{"issue":"1","key":"1775_CR148","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41408-021-00603-3","volume":"12","author":"W Fiskus","year":"2022","unstructured":"Fiskus W, Boettcher S, Daver N, Mill CP, Sasaki K, Birdwell CE, et al. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J. 2022;12(1):5.","journal-title":"Blood Cancer J"},{"issue":"17","key":"1775_CR149","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-024-01632-8","volume":"18","author":"KVG Nadiminti","year":"2024","unstructured":"Nadiminti KVG, Sahasrabudhe KD, Liu H. Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead. J Hematol OncolJ Hematol Oncol. 2024;18(17):113.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"Supplement 1","key":"1775_CR150","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2023-182337","volume":"142","author":"GC Issa","year":"2023","unstructured":"Issa GC, Cuglievan B, DiNardo CD, Short NJ, McCall D, Gibson A, et al. Early results of the phase I\/II study investigating the all-oral combination of the menin inhibitor revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax in acute myeloid leukemia (save). Blood. 2023;142(Supplement 1):58.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1775_CR151","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1182\/blood-2024-208678","volume":"144","author":"EG Emiliano","year":"2024","unstructured":"Emiliano EG, Santos GEAA, Miranda E, Duarte GO, Duffles G, De Souza C, et al. Impact of the 2022 who classification on chronic myeloid leukemia. Blood. 2024;144(Supplement 1):3157.","journal-title":"Blood"},{"issue":"5","key":"1775_CR152","first-page":"1517","volume":"94","author":"RT Silver","year":"1999","unstructured":"Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American society of hematology. Blood. 1999;94(5):1517\u201336.","journal-title":"Blood"},{"issue":"11","key":"1775_CR153","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1182\/blood-2010-09-308510","volume":"117","author":"Q Jiang","year":"2011","unstructured":"Jiang Q, Xu LP, Liu DH, Liu KY, Chen SS, Jiang B, et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood. 2011;117(11):3032\u201340.","journal-title":"Blood"},{"issue":"11","key":"1775_CR154","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ajh.27443","volume":"99","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2024;99(11):2191\u2013212.","journal-title":"Am J Hematol"},{"issue":"3","key":"1775_CR155","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.clml.2023.10.005","volume":"24","author":"AJ Klink","year":"2024","unstructured":"Klink AJ, Keating SJ, Brokars J, Feinberg B, Jabbour E. Real-world effectiveness of dasatinib versus imatinib in newly diagnosed patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2024;24(3):149\u201357.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"1775_CR156","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251\u20139.","journal-title":"N Engl J Med"},{"issue":"3","key":"1775_CR157","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","volume":"36","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36(3):231\u20137.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1775_CR158","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2024.5157","volume":"11","author":"E Jabbour","year":"2025","unstructured":"Jabbour E, Oehler VG, Koller PB, Jamy O, Lomaia E, Hunter AM, et al. Olverembatinib after failure of tyrosine kinase inhibitors, including ponatinib or asciminib: A phase 1b randomized clinical trial. JAMA Oncol. 2025;11(1):28\u201335.","journal-title":"JAMA Oncol"},{"issue":"10","key":"1775_CR159","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2400858","volume":"391","author":"A Hochhaus","year":"2024","unstructured":"Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, et al. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2024;391(10):885\u201398.","journal-title":"N Engl J Med"},{"issue":"15","key":"1775_CR160","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1002\/cncr.35317","volume":"130","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Haddad FG, Sasaki K, Carter BZ, Alvarado Y, Nasnas C, et al. Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer. 2024;130(15):2652\u20139.","journal-title":"Cancer"},{"key":"1775_CR161","unstructured":"M.D. Anderson Cancer Center. Phase II Study Assessing Safety and Clinical Activity of the Combination of ASTX727 With Dasatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) [Internet]. clinicaltrials.gov. 2025 Aug [cited 2025 Aug 20]. Report No: NCT05007873. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05007873."},{"issue":"Supplement 1","key":"1775_CR162","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1182\/blood-2023-182792","volume":"142","author":"A Hochhaus","year":"2023","unstructured":"Hochhaus A, Burchert A, Saussele S, Baerlocher GM, Mayer J, Br\u00fcmmendorf TH, et al. Treatment free remission after nilotinib plus peg-interferon alpha induction and peg-interferon alpha maintenance therapy for newly diagnosed chronic myeloid leukemia patients; the tiger trial. Blood. 2023;142(Supplement 1):446.","journal-title":"Blood"},{"issue":"74","key":"1775_CR163","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.leukres.2018.10.002","volume":"1","author":"K Sweet","year":"2018","unstructured":"Sweet K, Hazlehurst L, Sahakian E, Powers J, Nodzon L, Kayali F, et al. A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease. Leuk Res. 2018;1(74):89\u201396.","journal-title":"Leuk Res"},{"issue":"5","key":"1775_CR164","first-page":"935","volume":"8","author":"MH Cohen","year":"2002","unstructured":"Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res Off J Am Assoc Cancer Res. 2002;8(5):935\u201342.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"11","key":"1775_CR165","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","volume":"66","author":"JS Tokarski","year":"2006","unstructured":"Tokarski JS, Newitt JA, Chang CYJ, Cheng JD, Wittekind M, Kiefer SE, et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006;66(11):5790\u20137.","journal-title":"Cancer Res"},{"issue":"11","key":"1775_CR166","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/ajh.26689","volume":"97","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, et al. Low-dose dasatinib 50\u2009mg\/day versus standard-dose dasatinib 100\u2009mg\/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol. 2022;97(11):1413\u20138.","journal-title":"Am J Hematol"},{"issue":"2","key":"1775_CR167","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, Br\u00fcggen J, Cowan-Jacob SW, Ray A, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7(2):129\u201341.","journal-title":"Cancer Cell"},{"issue":"10","key":"1775_CR168","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1007\/s00277-023-05394-0","volume":"102","author":"S Isfort","year":"2023","unstructured":"Isfort S, Manz K, Teichmann LL, Crysandt M, Burchert A, Hochhaus A, et al. Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study. Ann Hematol. 2023;102(10):2741\u201352.","journal-title":"Ann Hematol"},{"issue":"9","key":"1775_CR169","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.7044","volume":"22","author":"VG Oehler","year":"2024","unstructured":"Oehler VG, Huang IJ, Siu C, Kim M, Signorelli J, Bell CS, et al. Dose modifications in the management of chronic phase chronic myeloid leukemia: who, what, and when. J Natl Compr Canc Netw. 2024;22(9):e247044.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"1775_CR170","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/17474086.2024.2440776","volume":"18","author":"A Lagan\u00e0","year":"2025","unstructured":"Lagan\u00e0 A, Scalzulli E, Bisegna ML, Ielo C, Martelli M, Breccia M. Understanding and overcoming resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). Expert Rev Hematol. 2025;18(1):65\u201379.","journal-title":"Expert Rev Hematol"},{"key":"1775_CR171","first-page":"1","volume":"12","author":"A Costa","year":"2025","unstructured":"Costa A, Scalzulli E, Bisegna ML, Breccia M. Asciminib in the treatment of chronic myeloid leukemia in chronic phase. Future Oncol Lond Engl. 2025;12:1\u201317.","journal-title":"Future Oncol Lond Engl"},{"issue":"11","key":"1775_CR172","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1002\/ajh.26686","volume":"97","author":"HM Kantarjian","year":"2022","unstructured":"Kantarjian HM, Jabbour E, Deininger M, Abruzzese E, Apperley J, Cortes J, et al. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia. Am J Hematol. 2022;97(11):1419\u201326.","journal-title":"Am J Hematol"},{"issue":"8","key":"1775_CR173","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1002\/ajh.27355","volume":"99","author":"HM Kantarjian","year":"2024","unstructured":"Kantarjian HM, Chifotides HT, Haddad FG, Short NJ, Loghavi S, Jabbour E. Ponatinib-review of historical development, current status, and future research. Am J Hematol. 2024;99(8):1576\u201385.","journal-title":"Am J Hematol"},{"issue":"3","key":"1775_CR174","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","volume":"26","author":"MS Zabriskie","year":"2014","unstructured":"Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014;26(3):428\u201342.","journal-title":"Cancer Cell"},{"issue":"19","key":"1775_CR175","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783\u201396.","journal-title":"N Engl J Med"},{"issue":"6","key":"1775_CR176","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1182\/blood-2015-12-685149","volume":"127","author":"G Saglio","year":"2016","unstructured":"Saglio G, Fava C. BCR-ABL1 mutation \u2260 ponatinib resistance. Blood. 2016;127(6):666\u20137.","journal-title":"Blood"},{"issue":"2","key":"1775_CR177","doi-asserted-by":"publisher","first-page":"13","DOI":"10.21037\/atm-25-28","volume":"13","author":"Y Kubota","year":"2025","unstructured":"Kubota Y. Olverembatinib for heavily pretreated BCR::ABL1-positive leukemia, including resistance or intolerance to ponatinib and\/or asciminib. Ann Transl Med. 2025;13(2):13\u201313.","journal-title":"Ann Transl Med"},{"issue":"4","key":"1775_CR178","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1214","volume":"12","author":"N Okamoto","year":"2024","unstructured":"Okamoto N, Yagi K, Imawaka S, Takaoka M, Aizawa F, Niimura T, et al. Asciminib, a novel allosteric inhibitor of BCR-ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance. Pharmacol Res Perspect. 2024;12(4):e1214.","journal-title":"Pharmacol Res Perspect"},{"issue":"7647","key":"1775_CR179","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nat. 2017;543(7647):733\u20137.","journal-title":"Nat"},{"issue":"4","key":"1775_CR180","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","volume":"36","author":"CA Eide","year":"2019","unstructured":"Eide CA, Zabriskie MS, Stevens SLS, Antelope O, Vellore NA, Than H, et al. Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell. 2019;36(4):431-443.e5.","journal-title":"Cancer Cell"},{"issue":"6","key":"1775_CR181","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.clml.2025.01.004","volume":"25","author":"A Costa","year":"2025","unstructured":"Costa A, Breccia M. SOHO state of the art updates and next questions: combination therapy in chronic myeloid leukemia in chronic phase. Clin Lymphoma Myeloma Leuk. 2025;25(6):421\u201331.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"355","key":"1775_CR182","doi-asserted-by":"publisher","first-page":"355ra117","DOI":"10.1126\/scitranslmed.aag1180","volume":"8","author":"BZ Carter","year":"2016","unstructured":"Carter BZ, Mak PY, Mu H, Zhou H, Mak DH, Schober W, et al. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med. 2016;8(355):355ra117.","journal-title":"Sci Transl Med"},{"issue":"2","key":"1775_CR183","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1053\/j.seminhematol.2018.08.002","volume":"56","author":"DA Arber","year":"2019","unstructured":"Arber DA. The 2016 WHO classification of acute myeloid leukemia: what the practicing clinician needs to know. Semin Hematol. 2019;56(2):90\u20135.","journal-title":"Semin Hematol"},{"issue":"8","key":"1775_CR184","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1200\/JCO.2011.35.6394","volume":"30","author":"J Schanz","year":"2012","unstructured":"Schanz J, T\u00fcchler H, Sol\u00e9 F, Mallo M, Lu\u00f1o E, Cervera J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820\u20139.","journal-title":"J Clin Oncol"},{"issue":"21","key":"1775_CR185","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1182\/bloodadvances.2018022434","volume":"3","author":"F Thol","year":"2019","unstructured":"Thol F, Platzbecker U. Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS? Blood Adv. 2019;3(21):3449\u201353.","journal-title":"Blood Adv"},{"issue":"2","key":"1775_CR186","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/leu.2013.336","volume":"28","author":"T Haferlach","year":"2014","unstructured":"Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2):241\u20137.","journal-title":"Leukemia"},{"issue":"1\u20132","key":"1775_CR187","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.cbi.2009.10.009","volume":"184","author":"JW Vardiman","year":"2010","unstructured":"Vardiman JW. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chem Biol Interact. 2010;184(1\u20132):16\u201320.","journal-title":"Chem Biol Interact"},{"issue":"20","key":"1775_CR188","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"11","key":"1775_CR189","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1182\/blood.2024025464","volume":"145","author":"JS Garcia","year":"2024","unstructured":"Garcia JS, Platzbecker U, Odenike O, Fleming SA, Fong CY, Borate U, et al. Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes. Blood. 2024;145(11):1126\u201335.","journal-title":"Blood"},{"issue":"17","key":"1775_CR190","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","volume":"6","author":"L Ad\u00e8s","year":"2022","unstructured":"Ad\u00e8s L, Girshova L, Doronin VA, D\u00edez-Campelo M, Valc\u00e1rcel D, Kambhampati S, et al. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML. Blood Adv. 2022;6(17):5132\u201345.","journal-title":"Blood Adv"},{"issue":"16","key":"1775_CR191","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-023-01476-8","volume":"8","author":"NJ Short","year":"2023","unstructured":"Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, et al. A phase 1\/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol OncolJ Hematol Oncol. 2023;8(16):73.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"15","key":"1775_CR192","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.1182\/bloodadvances.2023012302","volume":"8","author":"CD DiNardo","year":"2024","unstructured":"DiNardo CD, Roboz GJ, Watts JM, Madanat YF, Prince GT, Baratam P, et al. Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed\/refractory myelodysplastic syndrome. Blood Adv. 2024;8(15):4209\u201320.","journal-title":"Blood Adv"},{"issue":"3","key":"1775_CR193","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/bjh.17689","volume":"195","author":"KS Chien","year":"2021","unstructured":"Chien KS, Kim K, Nogueras-Gonzalez GM, Borthakur G, Naqvi K, Daver NG, et al. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol. 2021;195(3):378\u201387.","journal-title":"Br J Haematol"},{"issue":"4","key":"1775_CR194","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1182\/bloodadvances.2021005240","volume":"6","author":"AT Gerds","year":"2022","unstructured":"Gerds AT, Scott BL, Greenberg P, Lin TL, Pollyea DA, Verma A, et al. Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome. Blood Adv. 2022;6(4):1152\u201361.","journal-title":"Blood Adv"},{"issue":"24","key":"1775_CR195","doi-asserted-by":"publisher","first-page":"5306","DOI":"10.1158\/1078-0432.CCR-22-1810","volume":"28","author":"CL O\u2019Connell","year":"2022","unstructured":"O\u2019Connell CL, Baer MR, \u00d8rskov AD, Saini SK, Duong VH, Kropf P, et al. Safety, outcomes, and T-cell characteristics in patients with relapsed or refractory MDS or CMML treated with atezolizumab in combination with guadecitabine. Clin Cancer Res Off J Am Assoc Cancer Res. 2022;28(24):5306\u201316.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"1","key":"1775_CR196","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","volume":"11","author":"AM Zeidan","year":"2024","unstructured":"Zeidan AM, Ando K, Rauzy O, Turgut M, Wang MC, Cairoli R, et al. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2024;11(1):e38-50.","journal-title":"Lancet Haematol"},{"issue":"4","key":"1775_CR197","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1158\/1078-0432.CCR-20-3139","volume":"27","author":"E Anastasiadou","year":"2021","unstructured":"Anastasiadou E, Seto AG, Beatty X, Hermreck M, Gilles ME, Stroopinsky D, et al. Cobomarsen, an oligonucleotide Inhibitor of miR-155, slows DLBCL tumor cell growth in vitro and in vivo. Clin Cancer Res Off J Am Assoc Cancer Res. 2021;27(4):1139\u201349.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"9","key":"1775_CR198","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.leukres.2011.06.008","volume":"35","author":"M Nomdedeu","year":"2011","unstructured":"Nomdedeu M, Maffioli M, Calvo X, Mart\u00ednez-Trillos A, Baumann T, D\u00edaz-Bey\u00e1 M, et al. Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation. Leuk Res. 2011;35(9):1276\u20138.","journal-title":"Leuk Res"},{"issue":"2","key":"1775_CR199","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70086","volume":"9","author":"A Consagra","year":"2025","unstructured":"Consagra A, Lanino L, Al Ali NH, Aguirre L, Xie Z, Chan O, et al. Response to luspatercept can be predicted and improves overall survival in the real-life treatment of LR-MDS. HemaSphere. 2025;9(2):e70086.","journal-title":"HemaSphere"},{"issue":"3","key":"1775_CR200","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3390\/cancers17030508","volume":"17","author":"N Thalambedu","year":"2025","unstructured":"Thalambedu N, Mohan Lal B, Harbaugh B, Alapat DV, Gaddam M, Gentille Sanchez CG, et al. Unveiling myelodysplastic syndromes: exploring pathogenic mechanisms and therapeutic advances. Cancers. 2025;17(3):508.","journal-title":"Cancers"},{"issue":"Supplement 1","key":"1775_CR201","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2020-142003","volume":"136","author":"K Morita","year":"2020","unstructured":"Morita K, Kantarjian HM, Montalban Bravo G, Sasaki K, Daver N, Jabbour E, et al. A phase II study of double immune checkpoint inhibitor blockade with nivolumab and ipilimumab with or without azacitidine in patients with myelodysplastic syndrome (MDS). Blood. 2020;136(Supplement 1):7\u20139.","journal-title":"Blood"},{"issue":"2","key":"1775_CR202","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/pbc.22456","volume":"55","author":"Y Messinger","year":"2010","unstructured":"Messinger Y, Gaynon P, Raetz E, Hutchinson R, Dubois S, Glade-Bender J, et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer. 2010;55(2):254\u20139.","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"1775_CR203","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/bjh.14505","volume":"176","author":"A Bertaina","year":"2017","unstructured":"Bertaina A, Vinti L, Strocchio L, Gaspari S, Caruso R, Algeri M, et al. The combination of bortezomib with chemotherapy to treat\u00a0relapsed\/refractory acute lymphoblastic leukaemia of childhood. Br J Haematol. 2017;176(4):629\u201336.","journal-title":"Br J Haematol"},{"issue":"2","key":"1775_CR204","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2012-04-418640","volume":"120","author":"YH Messinger","year":"2012","unstructured":"Messinger YH, Gaynon PS, Sposto R, van der Giessen J, Eckroth E, Malvar J, et al. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: therapeutic advances in childhood leukemia & lymphoma (TACL) study. Blood. 2012;120(2):285\u201390.","journal-title":"Blood"},{"issue":"3","key":"1775_CR205","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28062","volume":"67","author":"KJ August","year":"2020","unstructured":"August KJ, Guest EM, Lewing K, Hays JA, Gamis AS. Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib. Pediatr Blood Cancer. 2020;67(3):e28062.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"1775_CR206","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s44313-024-00050-6","volume":"60","author":"CO Ramos Pe\u00f1afiel","year":"2025","unstructured":"Ramos Pe\u00f1afiel CO, P\u00e9rez S\u00e1mano D, Gallardo Rodr\u00edguez AG, Terreros Palacio C, Olarte Carrillo I, Mart\u00ednez Murillo C, et al. Efficacy of bortezomib combined with Hyper-CVAD in adults with relapsed acute lymphoblastic leukemia or positive measurable residual disease; effect of bortezomib in leukemia. Blood Res. 2025;60(1):4.","journal-title":"Blood Res"},{"issue":"12","key":"1775_CR207","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29999","volume":"69","author":"MJ Burke","year":"2022","unstructured":"Burke MJ, Ziegler DS, Bautista F, Attarbaschi A, Gore L, Locatelli F, et al. Phase 1b study of carfilzomib with induction chemotherapy in pediatric relapsed\/refractory acute lymphoblastic leukemia. Pediatr Blood Cancer. 2022;69(12):e29999.","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"1775_CR208","doi-asserted-by":"publisher","first-page":"E114","DOI":"10.1002\/ajh.26105","volume":"96","author":"BA Jonas","year":"2021","unstructured":"Jonas BA, Fisch SC, Rosenberg AS, Hoeg RT, Tuscano JM, Abedi M. Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2021;96(4):E114\u20137.","journal-title":"Am J Hematol"},{"issue":"10","key":"1775_CR209","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1016\/j.clml.2024.06.002","volume":"24","author":"MA Ali","year":"2024","unstructured":"Ali MA, Aiman W, Kantarjian H, Jabbour E, Ravandi F, Jain N, et al. Efficacy of chemotherapy-free regimens in the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia: A systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2024;24(10):e376\u201384.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"1775_CR210","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1001\/jamaoncol.2019.5868","volume":"6","author":"S Shen","year":"2020","unstructured":"Shen S, Chen X, Cai J, Yu J, Gao J, Hu S, et al. Effect of dasatinib vs imatinib in the treatment of pediatric philadelphia chromosome-positive acute lymphoblastic leukemia: A randomized clinical trial. JAMA Oncol. 2020;6(3):358\u201366.","journal-title":"JAMA Oncol"},{"issue":"21","key":"1775_CR211","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1001\/jama.2024.4783","volume":"331","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian HM, Aldoss I, Montesinos P, Leonard JT, G\u00f3mez-Almaguer D, et al. Ponatinib vs imatinib in frontline philadelphia chromosome-positive acute lymphoblastic leukemia: A randomized clinical trial. JAMA. 2024;331(21):1814\u201323.","journal-title":"JAMA"},{"issue":"Supplement 1","key":"1775_CR212","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1182\/blood-2021-153795","volume":"138","author":"NJ Short","year":"2021","unstructured":"Short NJ, Kantarjian H, Konopleva M, Desikan SPP, Jain N, Ravandi F, et al. Updated results of a phase II study of ponatinib and blinatumomab for patients with philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2021;138(Supplement 1):2298.","journal-title":"Blood"},{"key":"1775_CR213","unstructured":"St. Jude Children27;s Research Hospital. Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma [Internet]. clinicaltrials.gov. 2024 Nov [cited 2025 Mar 27]. Report No: NCT03117751. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03117751."},{"key":"1775_CR214","unstructured":"University of Chicago. Phase I Trial of Ruxolitinib in Combination With a Pediatric Based-regimen for Adolescents and Young Adults (AYAs) With Ph-like Acute Lymphoblastic Leukemia (ALL) [Internet]. clinicaltrials.gov. 2024 Dec [cited 2025 Mar 27]. Report No: NCT03571321. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03571321."},{"issue":"7","key":"1775_CR215","doi-asserted-by":"publisher","first-page":"E229","DOI":"10.1002\/ajh.26175","volume":"96","author":"NJ Short","year":"2021","unstructured":"Short NJ, Konopleva M, Kadia T, Kebriaei P, Daver N, Huang X, et al. An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed\/refractory philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. 2021;96(7):E229\u201332.","journal-title":"Am J Hematol"},{"key":"1775_CR216","unstructured":"Goekbuget N. An Open Label, Phase I2F;II Study of Venetoclax in Addition to Blinatumomab Immunotherapy in Adult Patients With Relapsed2F;Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) [Internet]. clinicaltrials.gov. 2024 May [cited 2025 Mar 26]. Report No: NCT05182385. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05182385."},{"key":"1775_CR217","unstructured":"Luskin M. A Phase 1 Study of Venetoclax in Combination with Inotuzumab Ozogamicin for B-cell Acute Lymphoblastic Leukemia (B-ALL) [Internet]. clinicaltrials.gov. 2025 Jan [cited 2025 Mar 26]. Report No: NCT05016947. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05016947."},{"issue":"13","key":"1775_CR218","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1182\/blood-2011-01-329441","volume":"118","author":"N G\u00f6kbuget","year":"2011","unstructured":"G\u00f6kbuget N, Basara N, Baurmann H, Beck J, Br\u00fcggemann M, Diedrich H, et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia\/lymphoma offers curative option with subsequent stem cell transplantation. Blood. 2011;118(13):3504\u201311.","journal-title":"Blood"},{"issue":"11","key":"1775_CR219","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29901","volume":"69","author":"JA Whitlock","year":"2022","unstructured":"Whitlock JA, Malvar J, Dalla-Pozza L, Goldberg JM, Silverman LB, Ziegler DS, et al. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR). Pediatr Blood Cancer. 2022;69(11):e29901.","journal-title":"Pediatr Blood Cancer"},{"issue":"28","key":"1775_CR220","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1200\/JCO.20.00256","volume":"38","author":"KP Dunsmore","year":"2020","unstructured":"Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, et al. Children\u2019s oncology group AALL0434: A phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38(28):3282\u201393.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"12","key":"1775_CR221","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1038\/s41375-024-02414-4","volume":"38","author":"F Ravandi","year":"2024","unstructured":"Ravandi F, Senapati J, Jain N, Short NJ, Kadia T, Borthakur G, et al. Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia. 2024;38(12):2717\u201321.","journal-title":"Leukemia"},{"issue":"21","key":"1775_CR222","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1182\/blood.2024024493","volume":"144","author":"T Bhatla","year":"2024","unstructured":"Bhatla T, Hogan LE, Teachey DT, Bautista F, Moppett J, Velasco Puy\u00f3 P, et al. Daratumumab in pediatric relapsed\/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study. Blood. 2024;144(21):2237\u201347.","journal-title":"Blood"},{"issue":"5","key":"1775_CR223","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1002\/cam4.4478","volume":"11","author":"N Boissel","year":"2022","unstructured":"Boissel N, Chevallier P, Doronin V, Griskevicius L, Maschan A, McCloskey J, et al. Isatuximab monotherapy in patients with refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma: phase 2 study. Cancer Med. 2022;11(5):1292\u20138.","journal-title":"Cancer Med"},{"issue":"Supplement 1","key":"1775_CR224","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1182\/blood-2021-150272","volume":"138","author":"A Baruchel","year":"2021","unstructured":"Baruchel A, Abrahamsson J, Bertrand Y, Gonzalez O, Nysom K, Quinones W, et al. Isatuximab in combination with chemotherapy in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia or acute myeloid leukemia (ISAKIDS): interim analysis. Blood. 2021;138(Supplement 1):516.","journal-title":"Blood"},{"issue":"9","key":"1775_CR225","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836\u201347.","journal-title":"N Engl J Med"},{"issue":"4","key":"1775_CR226","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1001\/jama.2021.8154","volume":"326","author":"F Locatelli","year":"2021","unstructured":"Locatelli F, Zugmaier G, von Stackelberg A. Blinatumomab vs chemotherapy among children with relapsed acute lymphoblastic leukemia-reply. JAMA. 2021;326(4):359\u201360.","journal-title":"JAMA"},{"issue":"9","key":"1775_CR227","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/jama.2021.0669","volume":"325","author":"PA Brown","year":"2021","unstructured":"Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ, et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: A randomized clinical trial. JAMA. 2021;325(9):833\u201342.","journal-title":"JAMA"},{"issue":"18","key":"1775_CR228","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","volume":"29","author":"MS Topp","year":"2011","unstructured":"Topp MS, Kufer P, G\u00f6kbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493\u20138.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1775_CR229","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2312948","volume":"391","author":"MR Litzow","year":"2024","unstructured":"Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N Engl J Med. 2024;391(4):320\u201333.","journal-title":"N Engl J Med"},{"issue":"17","key":"1775_CR230","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","volume":"388","author":"IM van der Sluis","year":"2023","unstructured":"van der Sluis IM, de Lorenzo P, Kotecha RS, Attarbaschi A, Escherich G, Nysom K, et al. Blinatumomab added to chemotherapy in infant lymphoblastic leukemia. N Engl J Med. 2023;388(17):1572\u201381.","journal-title":"N Engl J Med"},{"issue":"9","key":"1775_CR231","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2411680","volume":"392","author":"S Gupta","year":"2025","unstructured":"Gupta S, Rau RE, Kairalla JA, Rabin KR, Wang C, Angiolillo AL, et al. Blinatumomab in standard-Risk B-cell acute lymphoblastic leukemia in children. N Engl J Med. 2025;392(9):875\u201391.","journal-title":"N Engl J Med"},{"issue":"3","key":"1775_CR232","first-page":"596","volume":"110","author":"M Algeri","year":"2025","unstructured":"Algeri M, Massa M, Pagliara D, Bertaina V, Galaverna F, Pili I, et al. Outcomes of children and young adults with B-cell acute lymphoblastic leukemia given blinatumomab as last consolidation treatment before allogeneic hematopoietic stem cell transplantation. Haematol. 2025;110(3):596\u2013607.","journal-title":"Haematol"},{"key":"1775_CR233","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.leukres.2019.02.009","volume":"79","author":"AC King","year":"2019","unstructured":"King AC, Pappacena JJ, Tallman MS, Park JH, Geyer MB. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia. Leuk Res. 2019;79:27\u201333.","journal-title":"Leuk Res"},{"issue":"8","key":"1775_CR234","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41408-020-00345-8","volume":"10","author":"DJ DeAngelo","year":"2020","unstructured":"DeAngelo DJ, Advani AS, Marks DI, Stelljes M, Liedtke M, Stock W, et al. Inotuzumab ozogamicin for relapsed\/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer J. 2020;10(8):81.","journal-title":"Blood Cancer J"},{"issue":"14","key":"1775_CR235","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/cncr.32116","volume":"125","author":"HM Kantarjian","year":"2019","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, G\u00f6kbuget N, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125(14):2474\u201387.","journal-title":"Cancer"},{"issue":"10","key":"1775_CR236","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.3324\/haematol.2023.284409","volume":"109","author":"E Pennesi","year":"2024","unstructured":"Pennesi E, Brivio E, Ammerlaan ACJ, Jiang Y, Van der Velden VHJ, Beverloo HB, et al. Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial. Haematol. 2024;109(10):3157\u201366.","journal-title":"Haematol"},{"issue":"Supplement 1","key":"1775_CR237","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1182\/blood-2024-209438","volume":"144","author":"DJ DeAngelo","year":"2024","unstructured":"DeAngelo DJ, Yin J, Advani AS, Luger S, Fulcher J, Liedtke M, et al. Addition of Inotuzumab to a pediatric inspired chemotherapy regimen in young adult patients with B-cell acute lymphoblastic leukemia: findings from the alliance A041501 phase 3 randomized trial. Blood. 2024;144(Supplement 1):308.","journal-title":"Blood"},{"issue":"2","key":"1775_CR238","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S1470-2045(18)30011-1","volume":"19","author":"H Kantarjian","year":"2018","unstructured":"Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018;19(2):240\u20138.","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"1775_CR239","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/blood-2024-208742","volume":"144","author":"J Senapati","year":"2024","unstructured":"Senapati J, Jabbour E, Short NJ, Jain N, Haddad FG, Kadia TM, et al. Chemotherapy free regimen of inotuzumab ozogamicin and blinatumomab in frontline therapy of older patients with philadelphia negative B-cell acute lymphoblastic leukemia. Blood. 2024;144(Supplement 1):1442.","journal-title":"Blood"},{"issue":"5","key":"1775_CR240","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.clml.2011.03.033","volume":"11","author":"AD Schimmer","year":"2011","unstructured":"Schimmer AD, Herr W, H\u00e4nel M, Borthakur G, Frankel A, Horst HA, et al. Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study. Clin Lymphoma Myeloma Leuk. 2011;11(5):433\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"1775_CR241","first-page":"1243","volume":"31","author":"AM Tari","year":"2007","unstructured":"Tari AM, Guti\u00e9rrez-Puente Y, Monaco G, Stephens C, Sun T, Rosenblum M, et al. Liposome-incorporated Grb2 antisense oligodeoxynucleotide increases the survival of mice bearing bcr-abl-positive leukemia xenografts. Int J Oncol. 2007;31(5):1243\u201350.","journal-title":"Int J Oncol"},{"issue":"4","key":"1775_CR242","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/S2352-3026(18)30021-8","volume":"5","author":"M Ohanian","year":"2018","unstructured":"Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E, et al. Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: A single-centre, open-label, dose-escalation, phase 1\/1b trial. Lancet Haematol. 2018;5(4):e136\u201346.","journal-title":"Lancet Haematol"},{"issue":"2","key":"1775_CR243","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/cncr.26292","volume":"118","author":"J Cortes","year":"2012","unstructured":"Cortes J, Kantarjian H, Ball ED, DiPersio J, Kolitz JE, Fernandez HF, et al. Phase II randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer. 2012;118(2):418\u201327.","journal-title":"Cancer"},{"issue":"Spec Feature","key":"1775_CR244","first-page":"135","volume":"8","author":"L Raedler","year":"2015","unstructured":"Raedler L. Velcade (bortezomib) receives 2 new FDA indications: for retreatment of patients with multiple myeloma and for first-line treatment of patients with mantle-cell lymphoma. Am Health Drug Benefits. 2015;8(Spec Feature):135\u201340.","journal-title":"Am Health Drug Benefits"},{"issue":"67","key":"1775_CR245","first-page":"471","volume":"12","author":"T Mujtaba","year":"2011","unstructured":"Mujtaba T, Dou QP. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med. 2011;12(67):471\u201380.","journal-title":"Discov Med"},{"issue":"9","key":"1775_CR246","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.3390\/ijms22094502","volume":"22","author":"MW Lato","year":"2021","unstructured":"Lato MW, Przysucha A, Grosman S, Zawitkowska J, Lejman M. The new therapeutic strategies in pediatric t-cell acute lymphoblastic leukemia. Int J Mol Sci. 2021;22(9):4502.","journal-title":"Int J Mol Sci"},{"issue":"Suppl1","key":"1775_CR247","first-page":"132","volume":"18","author":"MS Hosseini","year":"2019","unstructured":"Hosseini MS, Mohammadi MH, Vahabpour Roudsari R, Jafari L, Mashati P, Gharehbaghian A. Proteasome inhibition by carfilzomib induced apotosis and autophagy in a T-cell acute lymphoblastic leukemia cell line. Iran J Pharm Res. 2019;18(Suppl1):132\u201345.","journal-title":"Iran J Pharm Res"},{"key":"1775_CR248","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.drup.2014.12.001","volume":"18","author":"D Niewerth","year":"2015","unstructured":"Niewerth D, Jansen G, Assaraf YG, Zweegman S, Kaspers GJL, Cloos J. Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resist Updat. 2015;18:18\u201335.","journal-title":"Drug Resist Updat"},{"issue":"7","key":"1775_CR249","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1756-8722-7-7","volume":"13","author":"D Niewerth","year":"2014","unstructured":"Niewerth D, Kaspers GJL, Assaraf YG, van Meerloo J, Kirk CJ, Anderl J, et al. Interferon-\u03b3-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines. J Hematol OncolJ Hematol Oncol. 2014;13(7):7.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"1","key":"1775_CR250","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1182\/hematology.2022000413","volume":"2022","author":"FG Haddad","year":"2022","unstructured":"Haddad FG, Short NJ. Evidence-based minireview: what is the optimal tyrosine kinase inhibitor for adults with newly diagnosed philadelphia chromosome-positive acute lymphoblastic leukemia? Hematol Am Soc Hematol Educ Program. 2022;2022(1):213\u20137.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"2","key":"1775_CR251","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","volume":"10","author":"ML Den Boer","year":"2009","unstructured":"Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JGCAM, Peters STCJM, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: A genome-wide classification study. Lancet Oncol. 2009;10(2):125\u201334.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1775_CR252","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","volume":"371","author":"KG Roberts","year":"2014","unstructured":"Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005\u201315.","journal-title":"N Engl J Med"},{"issue":"9","key":"1775_CR253","doi-asserted-by":"publisher","first-page":"e427","DOI":"10.3324\/haematol.2018.192088","volume":"103","author":"YY Ding","year":"2018","unstructured":"Ding YY, Stern JW, Jubelirer TF, Wertheim GB, Lin F, Chang F, et al. Clinical efficacy of ruxolitinib and chemotherapy in a child with philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure. Haematol. 2018;103(9):e427\u201331.","journal-title":"Haematol"},{"key":"1775_CR254","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.942053","volume":"10","author":"CE Downes","year":"2022","unstructured":"Downes CE, McClure BJ, McDougal DP, Heatley SL, Bruning JB, Thomas D, et al. JAK2 alterations in acute lymphoblastic leukemia: molecular insights for superior precision medicine strategies. Front Cell Dev Biol. 2022;10:942053.","journal-title":"Front Cell Dev Biol"},{"issue":"12","key":"1775_CR255","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1016\/j.celrep.2015.12.003","volume":"13","author":"JM Benito","year":"2015","unstructured":"Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, et al. MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199. Cell Rep. 2015;13(12):2715\u201327.","journal-title":"Cell Rep"},{"issue":"9","key":"1775_CR256","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1158\/0008-5472.CAN-18-0236","volume":"79","author":"E Diaz-Flores","year":"2019","unstructured":"Diaz-Flores E, Comeaux EQ, Kim KL, Melnik E, Beckman K, Davis KL, et al. Bcl-2 Is a therapeutic target for hypodiploid B-lineage acute lymphoblastic leukemia. Cancer Res. 2019;79(9):2339\u201351.","journal-title":"Cancer Res"},{"issue":"9","key":"1775_CR257","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/ng.3362","volume":"47","author":"U Fischer","year":"2015","unstructured":"Fischer U, Forster M, Rinaldi A, Risch T, Sungalee S, Warnatz HJ, et al. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet. 2015;47(9):1020\u20139.","journal-title":"Nat Genet"},{"issue":"18","key":"1775_CR258","doi-asserted-by":"publisher","first-page":"10957","DOI":"10.3390\/ijms231810957","volume":"23","author":"S Aumann","year":"2022","unstructured":"Aumann S, Shaulov A, Haran A, Gross Even-Zohar N, Vainstein V, Nachmias B. The emerging role of venetoclax-based treatments in acute lymphoblastic leukemia. Int J Mol Sci. 2022;23(18):10957.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1775_CR259","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00277-021-04699-2","volume":"101","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Qian JJ, Shen YJ, Hang SJ, Jin J, Zhu HH. The first report of complete remission following treatment with venetoclax plus prednisone in elderly patients with philadelphia chromosome-negative acute lymphoblastic leukemia. Ann Hematol. 2022;101(5):1141\u20134.","journal-title":"Ann Hematol"},{"issue":"3","key":"1775_CR260","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.hemonc.2019.10.002","volume":"14","author":"N Farhadfar","year":"2021","unstructured":"Farhadfar N, Li Y, May WS, Adams CB. Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature. Hematol Oncol Stem Cell Ther. 2021;14(3):246\u201351.","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"8027","key":"1775_CR261","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/s41586-024-07807-0","volume":"632","author":"P P\u00f6l\u00f6nen","year":"2024","unstructured":"P\u00f6l\u00f6nen P, Di Giacomo D, Seffernick AE, Elsayed A, Kimura S, Benini F, et al. The genomic basis of childhood T-lineage acute lymphoblastic leukemia. Nat. 2024;632(8027):1082\u201391.","journal-title":"Nat"},{"issue":"1","key":"1775_CR262","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/bloodadvances.2023010303","volume":"8","author":"S Shimony","year":"2024","unstructured":"Shimony S, DeAngelo DJ, Luskin MR. Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia. Blood Adv. 2024;8(1):23\u201336.","journal-title":"Blood Adv"},{"issue":"3","key":"1775_CR263","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41375-025-02529-2","volume":"39","author":"FM Hormann","year":"2025","unstructured":"Hormann FM, Rudd SG. Nelarabine in T-cell acute lymphoblastic leukemia: intracellular metabolism and molecular mode-of-action. Leukemia. 2025;39(3):531\u201342.","journal-title":"Leukemia"},{"issue":"6","key":"1775_CR264","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1634\/theoncologist.2006-0017","volume":"13","author":"MH Cohen","year":"2008","unstructured":"Cohen MH, Johnson JR, Justice R, Pazdur R. FDA drug approval summary: nelarabine (arranon) for the treatment of T-cell lymphoblastic leukemia\/lymphoma. Oncol. 2008;13(6):709\u201314.","journal-title":"Oncol"},{"issue":"7","key":"1775_CR265","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3390\/cancers10070240","volume":"10","author":"N Tsesmetzis","year":"2018","unstructured":"Tsesmetzis N, Paulin CBJ, Rudd SG, Herold N. Nucleobase and nucleoside analogues: resistance and re-sensitisation at the level of pharmacokinetics, pharmacodynamics and metabolism. Cancers. 2018;10(7):240.","journal-title":"Cancers"},{"issue":"7","key":"1775_CR266","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/bloodadvances.2022008280","volume":"7","author":"S Shimony","year":"2023","unstructured":"Shimony S, Liu Y, Valtis YK, Paolino JD, Place AE, Brunner AM, et al. Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma\/leukemia. Blood Adv. 2023;7(7):1092\u2013102.","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"1775_CR267","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1182\/blood-2021-152355","volume":"138","author":"CJ Rowntree","year":"2021","unstructured":"Rowntree CJ, Kirkwood AA, Clifton-Hadley L, Farah N, Mansour MR, Hussain J, et al. First analysis of the UKALL14 randomized trial to determine whether the addition of nelarabine to standard chemotherapy improves event free survival in adults with T-cell acute lymphoblastic leukaemia (CRUK\/09\/006). Blood. 2021;138(Supplement 1):366.","journal-title":"Blood"},{"issue":"6","key":"1775_CR268","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s00277-023-05231-4","volume":"102","author":"S Yi\u011fit Kaya","year":"2023","unstructured":"Yi\u011fit Kaya S, Bektas S, Askin AE, Bal\u0131kAyd\u0131n B, Mutlu YG, Sevindik \u00d6G. Pegaspargase, venetoclax, and nelarabine: a successful bridge to allogeneic hematopoietic stem cell transplantation in a relapsed\/refractory T-cell acute lymphoblastic leukemia patient. Ann Hematol. 2023;102(6):1599\u2013600.","journal-title":"Ann Hematol"},{"issue":"26","key":"1775_CR269","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H D\u00f6hner","year":"2000","unstructured":"D\u00f6hner H, Stilgenbauer S, Benner A, Leupolt E, Kr\u00f6ber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910\u20136.","journal-title":"N Engl J Med"},{"issue":"7574","key":"1775_CR270","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature15395","volume":"526","author":"DA Landau","year":"2015","unstructured":"Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526(7574):525\u201330.","journal-title":"Nature"},{"key":"1775_CR271","doi-asserted-by":"crossref","unstructured":"International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): A meta-analysis of individual patient data. Lancet Oncol. 2016 ;17(6):779\u201390.","DOI":"10.1016\/S1470-2045(16)30029-8"},{"issue":"1","key":"1775_CR272","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","volume":"48","author":"JL Binet","year":"1981","unstructured":"Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48(1):198\u2013206.","journal-title":"Cancer"},{"issue":"2","key":"1775_CR273","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","volume":"46","author":"KR Rai","year":"1975","unstructured":"Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219\u201334.","journal-title":"Blood"},{"key":"1775_CR274","doi-asserted-by":"crossref","unstructured":"Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists\u2019 Collaborative Group. J Natl Cancer Inst. ;91(10):861\u20138.","DOI":"10.1093\/jnci\/91.10.861"},{"issue":"8","key":"1775_CR275","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1182\/blood.V98.8.2319","volume":"98","author":"M Leporrier","year":"2001","unstructured":"Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 2001;98(8):2319\u201325.","journal-title":"Blood"},{"issue":"3","key":"1775_CR276","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/ajh.27546","volume":"100","author":"M Hallek","year":"2025","unstructured":"Hallek M. Chronic lymphocytic leukemia: 2025 update on the epidemiology, pathogenesis, diagnosis, and therapy. Am J Hematol. 2025;100(3):450\u201380.","journal-title":"Am J Hematol"},{"issue":"12","key":"1775_CR277","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.1182\/blood-2004-07-2669","volume":"105","author":"A Petlickovski","year":"2005","unstructured":"Petlickovski A, Laurenti L, Li X, Marietti S, Chiusolo P, Sica S, et al. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood. 2005;105(12):4820\u20137.","journal-title":"Blood"},{"issue":"23","key":"1775_CR278","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","volume":"117","author":"SEM Herman","year":"2011","unstructured":"Herman SEM, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287\u201396.","journal-title":"Blood"},{"issue":"25","key":"1775_CR279","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425\u201337.","journal-title":"N Engl J Med"},{"issue":"1","key":"1775_CR280","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40360-024-00832-9","volume":"26","author":"MA Karimi","year":"2025","unstructured":"Karimi MA, Norooziseyedhosseini H, Khademi R, Ghajary A, Kargar H, Abdollahi SS, et al. Real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies. BMC Pharmacol Toxicol. 2025;26(1):43.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"12","key":"1775_CR281","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1002\/cncr.30596","volume":"123","author":"P Jain","year":"2017","unstructured":"Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, et al. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017;123(12):2268\u201373.","journal-title":"Cancer"},{"issue":"13","key":"1775_CR282","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","volume":"35","author":"JA Woyach","year":"2017","unstructured":"Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, et al. BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(13):1437\u201343.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"31","key":"1775_CR283","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","volume":"39","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 2021;39(31):3441\u201352.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"1775_CR284","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/13543784.2018.1404027","volume":"27","author":"PA Thompson","year":"2018","unstructured":"Thompson PA, Burger JA. Bruton\u2019s tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). Expert Opin Investig Drugs. 2018;27(1):31\u201342.","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"1775_CR285","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/PPO.0000000000000416","volume":"25","author":"TJ Kipps","year":"2019","unstructured":"Kipps TJ, Choi MY. Targeted Therapy in Chronic Lymphocytic Leukemia. Cancer J Sudbury Mass. 2019;25(6):378\u201385.","journal-title":"Cancer J Sudbury Mass"},{"key":"1775_CR286","doi-asserted-by":"crossref","unstructured":"Garcia M, Croizier C, Lazarian G, Quinquenel A, Tassin T, Bourgne C, et al. Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors. Ann Hematol. 2025 Jan 24.","DOI":"10.1007\/s00277-025-06200-9"},{"issue":"10277","key":"1775_CR287","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","volume":"397","author":"AR Mato","year":"2021","unstructured":"Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1\/2 study. Lancet Lond Engl. 2021;397(10277):892\u2013901.","journal-title":"Lancet Lond Engl"},{"issue":"22","key":"1775_CR288","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","volume":"123","author":"JR Brown","year":"2014","unstructured":"Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia. Blood. 2014;123(22):3390\u20137.","journal-title":"Blood"},{"issue":"2","key":"1775_CR289","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","volume":"128","author":"BL Lampson","year":"2016","unstructured":"Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128(2):195\u2013203.","journal-title":"Blood"},{"issue":"10","key":"1775_CR290","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.3324\/haematol.2024.285043","volume":"109","author":"AV Danilov","year":"2024","unstructured":"Danilov AV, Flinn IW, Davids MS, Gregory B, Bentur O, Sidransky D, et al. The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: final analysis including overall survival. Haematol. 2024;109(10):3379\u201382.","journal-title":"Haematol"},{"issue":"17","key":"1775_CR291","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1007\/s40265-018-1013-4","volume":"78","author":"HA Blair","year":"2018","unstructured":"Blair HA. Duvelisib: first global approval. Drugs. 2018;78(17):1847\u201353.","journal-title":"Drugs"},{"issue":"17","key":"1775_CR292","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1158\/1078-0432.CCR-24-0967","volume":"30","author":"SS Sk\u00e5nland","year":"2024","unstructured":"Sk\u00e5nland SS, Okkenhaug K, Davids MS. PI3K inhibitors in hematology: when one door closes. Clin Cancer Res Off J Am Assoc Cancer Res. 2024;30(17):3667\u201375.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"20","key":"1775_CR293","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1182\/blood-2015-12-683516","volume":"127","author":"PM Barr","year":"2016","unstructured":"Barr PM, Saylors GB, Spurgeon SE, Cheson BD, Greenwald DR, O\u2019Brien SM, et al. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood. 2016;127(20):2411\u20135.","journal-title":"Blood"},{"issue":"6","key":"1775_CR294","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","volume":"17","author":"S Stilgenbauer","year":"2016","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768\u201378.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1775_CR295","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","volume":"18","author":"JF Seymour","year":"2017","unstructured":"Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: A phase 1b study. Lancet Oncol. 2017;18(2):230\u201340.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1775_CR296","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1200\/JCO.18.01580","volume":"37","author":"AP Kater","year":"2019","unstructured":"Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, et al. Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(4):269\u201377.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"26","key":"1775_CR297","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1182\/blood-2019-01-896290","volume":"133","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, Gribben JG, Dyer MJS, Wierda W, Maris MB, Furman RR, et al. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed\/refractory chronic lymphocytic leukemia. Blood. 2019;133(26):2765\u201375.","journal-title":"Blood"},{"key":"1775_CR298","unstructured":"Research C for DE and. FDA approves venetoclax for CLL and SLL. FDA [Internet]. 2019 Dec 20 [cited 2025 Mar 28]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-venetoclax-cll-and-sll."},{"issue":"3","key":"1775_CR299","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","volume":"9","author":"P Blombery","year":"2019","unstructured":"Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2019;9(3):342\u201353.","journal-title":"Cancer Discov"},{"issue":"12","key":"1775_CR300","doi-asserted-by":"publisher","first-page":"e879","DOI":"10.1016\/S2352-3026(21)00307-0","volume":"8","author":"JD Soumerai","year":"2021","unstructured":"Soumerai JD, Mato AR, Dogan A, Seshan VE, Joffe E, Flaherty K, et al. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial. Lancet Haematol. 2021;8(12):e879\u201390.","journal-title":"Lancet Haematol"},{"issue":"13","key":"1775_CR301","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1182\/blood.2024024510","volume":"144","author":"LE Roeker","year":"2024","unstructured":"Roeker LE, Woyach JA, Cheah CY, Coombs CC, Shah NN, Wierda WG, et al. Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed\/refractory CLL: the phase 1b BRUIN trial. Blood. 2024;144(13):1374\u201386.","journal-title":"Blood"},{"issue":"8","key":"1775_CR302","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1056\/NEJMoa2409804","volume":"392","author":"JR Brown","year":"2025","unstructured":"Brown JR, Seymour JF, Jurczak W, Aw A, Wach M, Illes A, et al. Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia. N Engl J Med. 2025;392(8):748\u201362.","journal-title":"N Engl J Med"},{"issue":"13","key":"1775_CR303","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.3390\/cancers15133346","volume":"15","author":"A Aureli","year":"2023","unstructured":"Aureli A, Marziani B, Venditti A, Sconocchia T, Sconocchia G. Acute lymphoblastic leukemia immunotherapy treatment: now, next, and beyond. Cancers. 2023;15(13):3346.","journal-title":"Cancers"},{"issue":"9","key":"1775_CR304","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1182\/blood-2018-01-826446","volume":"131","author":"J Wynne","year":"2018","unstructured":"Wynne J, Stock W. \u201cDar\u201d-ing to target CD38 in T-ALL. Blood. 2018;131(9):948\u20139.","journal-title":"Blood"},{"issue":"9","key":"1775_CR305","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","volume":"131","author":"KL Bride","year":"2018","unstructured":"Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018;131(9):995\u20139.","journal-title":"Blood"},{"issue":"3","key":"1775_CR306","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.3324\/haematol.2018.192757","volume":"104","author":"J Naik","year":"2019","unstructured":"Naik J, Themeli M, de Jong-Korlaar R, Ruiter RWJ, Poddighe PJ, Yuan H, et al. CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Haematol. 2019;104(3):e100\u20133.","journal-title":"Haematol"},{"key":"1775_CR307","unstructured":"Assistance Publique - H\u00f4pitaux de Paris. A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia [Internet]. clinicaltrials.gov. 2025 Feb [cited 2025 Apr 15]. Report No: NCT06860269. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06860269."},{"issue":"23","key":"1775_CR308","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/bloodadvances.2021005220","volume":"5","author":"KA Frerichs","year":"2021","unstructured":"Frerichs KA, Minnema MC, Levin MD, Broijl A, Bos GMJ, Kersten MJ, et al. Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed\/refractory multiple myeloma. Blood Adv. 2021;5(23):5128\u201339.","journal-title":"Blood Adv"},{"issue":"1","key":"1775_CR309","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood.2021014485","volume":"140","author":"K M\u00fcller","year":"2022","unstructured":"M\u00fcller K, Vogiatzi F, Winterberg D, R\u00f6sner T, Lenk L, Bastian L, et al. Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL. Blood. 2022;140(1):45\u201357.","journal-title":"Blood"},{"issue":"1","key":"1775_CR310","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood.2022016774","volume":"140","author":"C Diorio","year":"2022","unstructured":"Diorio C, Teachey DT. Please eat me! targeting CD47 and CD38 in T-ALL. Blood. 2022;140(1):6\u20138.","journal-title":"Blood"},{"issue":"2","key":"1775_CR311","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.htct.2023.06.006","volume":"46","author":"R Mirfakhraie","year":"2024","unstructured":"Mirfakhraie R, Dehaghi BK, Ghorbi MD, Ghaffari-Nazari H, Mohammadian M, Salimi M, et al. All about blinatumomab: the bispecific T cell engager immunotherapy for B cell acute lymphoblastic leukemia. Hematol Transfus Cell Ther. 2024;46(2):192\u2013200.","journal-title":"Hematol Transfus Cell Ther"},{"key":"1775_CR312","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2147\/BLCTT.S223894","volume":"10","author":"AM Sigmund","year":"2020","unstructured":"Sigmund AM, Sahasrabudhe KD, Bhatnagar B. Evaluating blinatumomab for the treatment of relapsed\/refractory ALL: design, development, and place in therapy. Blood Lymphat Cancer Targets Ther. 2020;10:7\u201320.","journal-title":"Blood Lymphat Cancer Targets Ther"},{"key":"1775_CR313","unstructured":"Research C for DE and. FDA granted accelerated approval to blinatumomab (Blincyto, Amgen Inc.) for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia. FDA [Internet]. 2024 Sep 8 [cited 2025 Apr 16]: Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-granted-accelerated-approval-blinatumomab-blincyto-amgen-inc-treatment-adult-and-pediatric."},{"key":"1775_CR314","unstructured":"Research C for DE and. FDA approves blinatumomab as consolidation for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. FDA [Internet]. 2024 Sep 8 [cited 2025 May 21]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-blinatumomab-consolidation-cd19-positive-philadelphia-chromosome-negative-b-cell."},{"issue":"11","key":"1775_CR315","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1080\/10428194.2020.1780583","volume":"61","author":"N G\u00f6kbuget","year":"2020","unstructured":"G\u00f6kbuget N, Zugmaier G, Dombret H, Stein A, Bonifacio M, Graux C, et al. Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2020;61(11):2665\u201373.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"1775_CR316","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2021.0987","volume":"325","author":"F Locatelli","year":"2021","unstructured":"Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: A randomized clinical trial. JAMA. 2021;325(9):843\u201354.","journal-title":"JAMA"},{"issue":"2","key":"1775_CR317","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2991\/chi.d.190219.001","volume":"1","author":"E Jacoby","year":"2019","unstructured":"Jacoby E. Relapse and resistance to CAR-T cells and blinatumomab in hematologic malignancies. Clin Hematol Int. 2019;1(2):79\u201384.","journal-title":"Clin Hematol Int"},{"key":"1775_CR318","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejca.2020.12.022","volume":"146","author":"G Martinelli","year":"2021","unstructured":"Martinelli G, Boissel N, Chevallier P, Ottmann O, G\u00f6kbuget N, Rambaldi A, et al. Long-term follow-up of blinatumomab in patients with relapsed\/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: final analysis of ALCANTARA study. Eur J Cancer. 2021;146:107\u201314.","journal-title":"Eur J Cancer"},{"issue":"6","key":"1775_CR319","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.3390\/jcm14062055","volume":"14","author":"M Canichella","year":"2025","unstructured":"Canichella M, De Fazio L, Molica M. Integrating blinatumomab in the frontline treatment in B-cell acute lymphoblastic leukemia: A new era in therapeutic management. J Clin Med. 2025;14(6):2055.","journal-title":"J Clin Med"},{"key":"1775_CR320","unstructured":"Research C for DE and. FDA approves inotuzumab ozogamicin for relapsed or refractory B-cell precursor ALL. FDA [Internet]. 2024 Sep 8 [cited 2025 Apr 17]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-inotuzumab-ozogamicin-relapsed-or-refractory-b-cell-precursor-all."},{"issue":"5","key":"1775_CR321","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/j.clml.2024.12.016","volume":"25","author":"EJ Jabbour","year":"2025","unstructured":"Jabbour EJ, Rousselot P, Gokbuget N, Chevallier P, Kantarjian HM, Stelljes M. Inotuzumab ozogamicin as first-line therapy in acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2025;25(5):e302\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"1775_CR322","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/17512433.2018.1478725","volume":"11","author":"J Baron","year":"2018","unstructured":"Baron J, Wang ES. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol. 2018;11(6):549\u201359.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1775_CR323","unstructured":"Research C for DE and. FDA Approves Gemtuzumab Ozogamicin for CD33-positive AML. FDA [Internet]. 2019 Sep 2 [cited 2025 Apr 1]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-gemtuzumab-ozogamicin-cd33-positive-aml."},{"issue":"9825","key":"1775_CR324","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne S, Pautas C, Terr\u00e9 C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study. Lancet Lond Engl. 2012;379(9825):1508\u201316.","journal-title":"Lancet Lond Engl"},{"issue":"21","key":"1775_CR325","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1182\/blood.V124.21.376.376","volume":"124","author":"S Castaigne","year":"2014","unstructured":"Castaigne S, Pautas C, Terr\u00e9 C, Renneville A, Gardin C, Suarez F, et al. Final analysis of the ALFA 0701 Study. Blood. 2014;124(21):376.","journal-title":"Blood"},{"issue":"171","key":"1775_CR326","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116132","volume":"1","author":"Y Wu","year":"2024","unstructured":"Wu Y, Li Y, Gao Y, Zhang P, Jing Q, Zhang Y, et al. Immunotherapies of acute myeloid leukemia: rationale, clinical evidence and perspective. Biomed Pharmacother. 2024;1(171):116132.","journal-title":"Biomed Pharmacother"},{"key":"1775_CR327","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12913-023-09054-x","volume":"16;23(1)","author":"R Cairoli","year":"2023","unstructured":"Cairoli R, Furneri G, Di Virgilio R, Veggia B, Ferrara F. Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive acute myeloid leukaemia (AML) in Italy. BMC Health Serv Res. 2023;16;23(1):36.","journal-title":"BMC Health Serv Res"},{"issue":"134","key":"1775_CR328","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1182\/blood-2019-128648","volume":"13","author":"NG Daver","year":"2019","unstructured":"Daver NG, Montesinos P, DeAngelo DJ, Wang ES, Papadantonakis N, Deconinck E, et al. Clinical profile of IMGN632, a novel CD123-targeting antibody-drug conjugate (ADC), in patients with relapsed\/refractory (R\/R) acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood. 2019;13(134):734.","journal-title":"Blood"},{"issue":"1","key":"1775_CR329","first-page":"208","volume":"12","author":"A Collados-Ros","year":"2024","unstructured":"Collados-Ros A, Muro M, Legaz I. Gemtuzumab ozogamicin in acute myeloid leukemia: efficacy, toxicity, and resistance mechanisms-a systematic review. Biomed. 2024;12(1):208.","journal-title":"Biomed"},{"issue":"8","key":"1775_CR330","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, et al. Immune checkpoint therapy\u2014current perspectives and future directions. Cell. 2023;186(8):1652\u201369.","journal-title":"Cell"},{"issue":"14","key":"1775_CR331","doi-asserted-by":"publisher","first-page":"1265299","DOI":"10.3389\/fimmu.2023.1265299","volume":"26","author":"H Cao","year":"2023","unstructured":"Cao H, Wu T, Zhou X, Xie S, Sun H, Sun Y, et al. Progress of research on PD-1\/PD-L1 in leukemia. Front Immunol. 2023;26(14):1265299.","journal-title":"Front Immunol"},{"issue":"1","key":"1775_CR332","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12935-023-02902-0","volume":"23","author":"HE Marei","year":"2023","unstructured":"Marei HE, Hasan A, Pozzoli G, Cenciarelli C. Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. Cancer Cell Int. 2023;23(1):64.","journal-title":"Cancer Cell Int"},{"key":"1775_CR333","unstructured":"Research C for DE and. Nivolumab (Opdivo) for Hodgkin Lymphoma. FDA [Internet]. 2019 Sep 2 [cited 2025 Apr 1]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/nivolumab-opdivo-hodgkin-lymphoma."},{"key":"1775_CR334","unstructured":"Research C for DE and. FDA extends approval of pembrolizumab for classical Hodgkin lymphoma. FDA [Internet]. 2024 Sep 8 [cited 2025 Apr 2]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-extends-approval-pembrolizumab-classical-hodgkin-lymphoma."},{"issue":"4","key":"1775_CR335","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/cncr.34566","volume":"129","author":"Z Zeng","year":"2023","unstructured":"Zeng Z, Maiti A, Herbrich S, Cai T, Cavazos A, Manzella T, et al. Triple combination targeting methyltransferase, BCL-2, and PD-1 facilitates antileukemia responses in acute myeloid leukemia. Cancer. 2023;129(4):531\u201340.","journal-title":"Cancer"},{"issue":"14","key":"1775_CR336","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.3390\/cells11142249","volume":"11","author":"Y Abaza","year":"2022","unstructured":"Abaza Y, Zeidan AM. Immune checkpoint inhibition in acute myeloid leukemia and myelodysplastic syndromes. Cells. 2022;11(14):2249.","journal-title":"Cells"},{"issue":"2","key":"1775_CR337","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/vaccines13020114","volume":"13","author":"FAS Mathias","year":"2025","unstructured":"Mathias FAS, Carvalho MGR, Ruiz JC. Therapeutic vaccines for hematological cancers: A scoping review of this immunotherapeutic approach as alternative to the treatment of these malignancies. Vaccines. 2025;13(2):114.","journal-title":"Vaccines"},{"issue":"1","key":"1775_CR338","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/14796694.2024.2433935","volume":"21","author":"O Jamy","year":"2025","unstructured":"Jamy O, Cicic D. REGAL: galinpepimut-S vs. best available therapy as maintenance therapy for acute myeloid leukemia in second remission. Future Oncol. 2025;21(1):73\u201381.","journal-title":"Future Oncol"},{"issue":"5","key":"1775_CR339","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jcyt.2024.02.009","volume":"26","author":"J MotallebzadehKhanmiri","year":"2024","unstructured":"MotallebzadehKhanmiri J, Alizadeh M, Esmaeili S, Gholami Z, Safarzadeh A, Khani-Eshratabadi M, et al. Dendritic cell vaccination strategy for the treatment of acute myeloid leukemia: A systematic review. Cytotherapy. 2024;26(5):427\u201335.","journal-title":"Cytotherapy"},{"issue":"5","key":"1775_CR340","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3390\/jcm8050579","volume":"8","author":"HH Van Acker","year":"2019","unstructured":"Van Acker HH, Versteven M, Lichtenegger FS, Roex G, Campillo-Davo D, Lion E, et al. Dendritic cell-based immunotherapy of acute myeloid leukemia. J Clin Med. 2019;8(5):579.","journal-title":"J Clin Med"},{"issue":"6","key":"1775_CR341","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1159\/000512452","volume":"47","author":"DC Amberger","year":"2020","unstructured":"Amberger DC, Schmetzer HM. Dendritic cells of leukemic origin: specialized antigen-presenting cells as potential treatment tools for patients with myeloid leukemia. Transfus Med Hemotherapy Off Organ Dtsch Ges Transfusionsmed Immunhamatol. 2020;47(6):432\u201343.","journal-title":"Transfus Med Hemotherapy Off Organ Dtsch Ges Transfusionsmed Immunhamatol"},{"issue":"11","key":"1775_CR342","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40164-022-00257-2","volume":"24","author":"J Yu","year":"2022","unstructured":"Yu J, Sun H, Cao W, Song Y, Jiang Z. Research progress on dendritic cell vaccines in cancer immunotherapy. Exp Hematol Oncol. 2022;24(11):3.","journal-title":"Exp Hematol Oncol"},{"issue":"4","key":"1775_CR343","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/bjh.15818","volume":"185","author":"MR Nahas","year":"2019","unstructured":"Nahas MR, Stroopinsky D, Rosenblatt J, Cole L, Pyzer AR, Anastasiadou E, et al. Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell\/AML vaccine. Br J Haematol. 2019;185(4):679\u201390.","journal-title":"Br J Haematol"},{"issue":"7","key":"1775_CR344","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","volume":"17","author":"B Eichhorst","year":"2016","unstructured":"Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928\u201342.","journal-title":"Lancet Oncol"},{"issue":"9980","key":"1775_CR345","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","volume":"385","author":"P Hillmen","year":"2015","unstructured":"Hillmen P, Robak T, Janssens A, Babu KG, Kloczko J, Grosicki S, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (complement 1): A randomised, multicentre, open-label phase 3 trial. Lancet Lond Engl. 2015;385(9980):1873\u201383.","journal-title":"Lancet Lond Engl"},{"issue":"7","key":"1775_CR346","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1200\/JCO-24-02503","volume":"43","author":"MS Davids","year":"2025","unstructured":"Davids MS, Ryan CE, Lampson BL, Ren Y, Tyekucheva S, Fernandes SM, et al. Phase II study of acalabrutinib, venetoclax, and obinutuzumab in a treatment-na\u00efve chronic lymphocytic leukemia population enriched for high-risk disease. J Clin Oncol Off J Am Soc Clin Oncol. 2025;43(7):788\u201399.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"1775_CR347","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/ajh.27569","volume":"100","author":"JE Bruno","year":"2025","unstructured":"Bruno JE, Herne CA, Baran AM, VanDerMeid KR, Barr PM, Williams AR, et al. Treatment of relapsed\/refractory CLL patients with PI3K\u03b4 inhibitor and anti-CD20 antibody rapidly decreases\u00a0tumor burden but could induce resistance. Am J Hematol. 2025;100(3):523\u20136.","journal-title":"Am J Hematol"},{"issue":"12","key":"1775_CR348","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.837531","volume":"21","author":"F Perutelli","year":"2022","unstructured":"Perutelli F, Jones R, Griggio V, Vitale C, Coscia M. Immunotherapeutic strategies in chronic lymphocytic leukemia: advances and challenges. Front Oncol. 2022;21(12):837531.","journal-title":"Front Oncol"},{"key":"1775_CR349","unstructured":"Woyach J. A Phase II Study of MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(CLL) 2F;Small Lymphocytic Lymphoma (SLL)2F;Prolymphocytic Leukemia (PLL), Including Those Who Have Relapsed on Ibrutinib, or Patients With Untreated CLL2F;SLL2F;PLL and an Open Pilot Study for Patients With Richters Transformation (RT) [Internet]. clinicaltrials.gov. 2024 May [cited 2025 Apr 3]. Report No: NCT02005289. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02005289."},{"issue":"14","key":"1775_CR350","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1080\/10428194.2021.1964020","volume":"62","author":"PB Staber","year":"2021","unstructured":"Staber PB, Jurczak W, Greil R, Vucinic V, Middeke JM, Montillo M, et al. Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor. Leuk Lymphoma. 2021;62(14):3440\u201351.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"1775_CR351","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/bjh.14464","volume":"176","author":"T Robak","year":"2017","unstructured":"Robak T, Hellmann A, Kloczko J, Loscertales J, Lech-Maranda E, Pagel JM, et al. Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia. Br J Haematol. 2017;176(4):618\u201328.","journal-title":"Br J Haematol"},{"issue":"4","key":"1775_CR352","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s10637-020-01056-4","volume":"39","author":"AV Danilov","year":"2021","unstructured":"Danilov AV, Spurgeon SE, Siddiqi T, Quinson AM, Maier D, Smith D, et al. A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia. Invest New Drugs. 2021;39(4):1099\u2013105.","journal-title":"Invest New Drugs"},{"issue":"1","key":"1775_CR353","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s40425-019-0710-1","volume":"7","author":"D Mahadevan","year":"2019","unstructured":"Mahadevan D, Lanasa MC, Farber C, Pandey M, Whelden M, Faas SJ, et al. Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200. J Immunother Cancer. 2019;7(1):227.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1775_CR354","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100001","volume":"1","author":"ML Wang","year":"2022","unstructured":"Wang ML, Barrientos JC, Furman RR, Mei M, Barr PM, Choi MY, et al. Zilovertamab vedotin targeting of ROR1 as therapy for lymphoid cancers. NEJM Evid. 2022;1(1):EVIDoa2100001.","journal-title":"NEJM Evid"},{"issue":"Supplement 1","key":"1775_CR355","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2020-137629","volume":"136","author":"KA Rogers","year":"2020","unstructured":"Rogers KA, Flinn IW, McGarry C, Gou LC, Hassounah N, Woo J, et al. Phase Ib study of Ianalumab (VAY736) and Ibrutinib in patients with chronic lymphocytic leukemia (CLL) on Ibrutinib therapy. Blood. 2020;136(Supplement 1):13\u20134.","journal-title":"Blood"},{"issue":"1","key":"1775_CR356","doi-asserted-by":"publisher","first-page":"6822","DOI":"10.1038\/s41467-024-51264-2","volume":"15","author":"R Gui\u00e8ze","year":"2024","unstructured":"Gui\u00e8ze R, Ysebaert L, Roos-Weil D, Fornecker LM, Ferrant E, Molina L, et al. Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial. Nat Commun. 2024;15(1):6822.","journal-title":"Nat Commun"},{"issue":"2","key":"1775_CR357","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","volume":"6","author":"A Younes","year":"2019","unstructured":"Younes A, Brody J, Carpio C, Lopez-Guillermo A, Ben-Yehuda D, Ferhanoglu B, et al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-hodgkin lymphoma or chronic lymphocytic leukaemia: A phase 1\/2a study. Lancet Haematol. 2019;6(2):e67-78.","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"1775_CR358","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1182\/blood-2018-99-117526","volume":"132","author":"AR Mato","year":"2018","unstructured":"Mato AR, Svoboda J, LuningPrak ET, Schuster SJ, Tsao P, Dorsey C, et al. Phase I\/II study of umbralisib (TGR-1202) in combination with ublituximab (TG-1101) and pembrolizumab in patients with relapsed\/refractory CLL and richter\u2019s transformation. Blood. 2018;132(Supplement 1):297.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1775_CR359","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1182\/blood-2021-154279","volume":"138","author":"N Jain","year":"2021","unstructured":"Jain N, Ferrajoli A, Thompson PA, Konopleva M, Green MR, Sampath D, et al. Venetoclax, obinutuzumab and atezolizumab (PD-L1 checkpoint inhibitor) for treatment for patients with richter transformation. Blood. 2021;138(Supplement 1):1550.","journal-title":"Blood"},{"issue":"31","key":"1775_CR360","doi-asserted-by":"publisher","first-page":"5208","DOI":"10.1200\/JCO.2009.22.5748","volume":"27","author":"S O\u2019Brien","year":"2009","unstructured":"O\u2019Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki AB, Koziner B, et al. 5-Year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol. 2009;27(31):5208\u201312.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1775_CR361","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1158\/1078-0432.CCR-07-1320","volume":"14","author":"RB Klisovic","year":"2008","unstructured":"Klisovic RB, Stock W, Cataland S, Klisovic MI, Liu S, Blum W, et al. A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin Cancer Res. 2008;14(8):2444\u20139.","journal-title":"Clin Cancer Res"},{"issue":"24","key":"1775_CR362","doi-asserted-by":"publisher","first-page":"9531","DOI":"10.3390\/ijms21249531","volume":"21","author":"M Bobrowicz","year":"2020","unstructured":"Bobrowicz M, Kubacz M, Slusarczyk A, Winiarska M. CD37 in B cell derived tumors-more than just a docking point for monoclonal antibodies. Int J Mol Sci. 2020;21(24):9531.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1775_CR363","first-page":"1383","volume":"10","author":"T Robak","year":"2009","unstructured":"Robak T, Robak P, Smolewski P. TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr Opin Investig Drugs Lond Engl 2000. 2009;10(12):1383\u201390.","journal-title":"Curr Opin Investig Drugs Lond Engl 2000"},{"key":"1775_CR364","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.coi.2021.06.014","volume":"71","author":"E Schweighoffer","year":"2021","unstructured":"Schweighoffer E, Tybulewicz VL. BAFF signaling in health and disease. Curr Opin Immunol. 2021;71:124\u201331.","journal-title":"Curr Opin Immunol"},{"issue":"10","key":"1775_CR365","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102725","volume":"12","author":"C Tandler","year":"2020","unstructured":"Tandler C, Schmidt M, Heitmann JS, Hierold J, Schmidt J, Schneider P, et al. Neutralization of B-cell activating factor (BAFF) by belimumab reinforces small molecule inhibitor treatment in chronic lymphocytic leukemia. Cancers. 2020;12(10):2725.","journal-title":"Cancers"},{"issue":"19","key":"1775_CR366","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1182\/blood.2020009686","volume":"138","author":"M Mhibik","year":"2021","unstructured":"Mhibik M, Gaglione EM, Eik D, Kendall EK, Blackburn A, Keyvanfar K, et al. BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19\/CD3-bispecific antibody in CLL. Blood. 2021;138(19):1843\u201354.","journal-title":"Blood"},{"issue":"149","key":"1775_CR367","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2025.107642","volume":"1","author":"ZD Epstein-Peterson","year":"2025","unstructured":"Epstein-Peterson ZD, Gurumurthi A, Horwitz SM. New treatments for adult T-cell leukemia\/lymphoma. Leuk Res. 2025;1(149):107642.","journal-title":"Leuk Res"},{"issue":"8","key":"1775_CR368","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41417-021-00418-1","volume":"29","author":"M Sheykhhasan","year":"2022","unstructured":"Sheykhhasan M, Manoochehri H, Dama P. Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: A review study. Cancer Gene Ther. 2022;29(8):1080\u201396.","journal-title":"Cancer Gene Ther"},{"issue":"4","key":"1775_CR369","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s12185-024-03809-w","volume":"120","author":"S Saito","year":"2024","unstructured":"Saito S, Nakazawa Y. CAR-T cell therapy in AML: recent progress and future perspectives. Int J Hematol. 2024;120(4):455\u201366.","journal-title":"Int J Hematol"},{"issue":"16","key":"1775_CR370","doi-asserted-by":"publisher","first-page":"204062072513268","DOI":"10.1177\/20406207251326802","volume":"25","author":"H Deng","year":"2025","unstructured":"Deng H, Wang Q, Tong X, Cui Z, Yang Y, Xiang Y. Recent advances of CAR-T cells in acute myeloid leukemia. Ther Adv Hematol. 2025;25(16):20406207251326800.","journal-title":"Ther Adv Hematol"},{"issue":"Supplement 1","key":"1775_CR371","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1182\/blood-2023-179667","volume":"142","author":"NN Shah","year":"2023","unstructured":"Shah NN, Tasian SK, Kohler ME, Hsieh EM, Baumeister SHC, Summers C, et al. CD33 CAR T-cells (CD33CART) for children and young adults with relapsed\/refractory AML: dose-escalation results from a phase I\/II multicenter trial. Blood. 2023;142(Supplement 1):771.","journal-title":"Blood"},{"key":"1775_CR372","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111299","volume":"137","author":"Z Wu","year":"2021","unstructured":"Wu Z, Zhang H, Wu M, Peng G, He Y, Wan N, et al. Targeting the NKG2D\/NKG2D-L axis in acute myeloid leukemia. Biomed Pharmacother. 2021;137:111299.","journal-title":"Biomed Pharmacother"},{"issue":"Supplement 1","key":"1775_CR373","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1182\/blood-2023-173582","volume":"142","author":"CS Sauter","year":"2023","unstructured":"Sauter CS, Borthakur G, Mountjoy L, Rotta M, Liu H, Murthy HS, et al. A phase 1 study of NKX101, a Chimeric antigen receptor natural killer (CAR-NK) cell therapy, with fludarabine and cytarabine in patients with acute myeloid leukemia. Blood. 2023;142(Supplement 1):2097.","journal-title":"Blood"},{"issue":"3","key":"1775_CR374","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","volume":"10","author":"DA Sallman","year":"2023","unstructured":"Sallman DA, Kerre T, Havelange V, Poir\u00e9 X, Lewalle P, Wang ES, et al. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. Lancet Haematol. 2023;10(3):e191-202.","journal-title":"Lancet Haematol"},{"issue":"3","key":"1775_CR375","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2174\/1871529X19666190627100613","volume":"19","author":"M Shi","year":"2019","unstructured":"Shi M, Su RJ, Parmar KP, Chaudhry R, Sun K, Rao J, et al. CD123: A novel biomarker for diagnosis and treatment of leukemia. Cardiovasc Hematol Disord Drug Targets. 2019;19(3):195\u2013204.","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"issue":"Supplement 1","key":"1775_CR376","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1182\/blood-2022-169928","volume":"14","author":"DA Sallman","year":"2022","unstructured":"Sallman DA, DeAngelo DJ, Pemmaraju N, Dinner S, Gill S, Olin RL, et al. Ameli-01 A phase I trial of UCART123v1.2, an anti-CD123 allogeneic CAR-T Cell product, in adult patients with relapsed or refractory(R\/R) CD123+ acute myeloid leukemia (AML). Blood. 2022;14(Supplement 1):2371\u20133.","journal-title":"Blood"},{"issue":"3","key":"1775_CR377","doi-asserted-by":"publisher","first-page":"2275457","DOI":"10.1080\/21645515.2023.2275457","volume":"19","author":"DT Peters","year":"2023","unstructured":"Peters DT, Savoldo B, Grover NS. Building safety into CAR-T therapy. Hum Vaccines Immunother. 2023;19(3):2275457.","journal-title":"Hum Vaccines Immunother"},{"issue":"2021","key":"1775_CR378","doi-asserted-by":"publisher","first-page":"6643948","DOI":"10.1155\/2021\/6643948","volume":"11","author":"J Wang","year":"2021","unstructured":"Wang J, Wang W, Chen H, Li W, Huang T, Zhang W, et al. C-type lectin-like molecule-1 as a biomarker for diagnosis and prognosis in acute myeloid leukemia: A preliminary study. BioMed Res Int. 2021;11(2021):6643948.","journal-title":"BioMed Res Int"},{"issue":"1","key":"1775_CR379","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","volume":"15","author":"X Jin","year":"2022","unstructured":"Jin X, Zhang M, Sun R, Lyu H, Xiao X, Zhang X, et al. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia. J Hematol OncolJ Hematol Oncol. 2022;15(1):88.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"Supplement 1","key":"1775_CR380","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1182\/blood-2023-180387","volume":"142","author":"X Zhang","year":"2023","unstructured":"Zhang X, Lv H, Xiao X, Bai X, Liu P, Pu Y, et al. A phase i clinical trial of CLL-1 CAR-T cells for the treatment of relapsed\/refractory acute myeloid leukemia in adults. Blood. 2023;142(Supplement 1):2106.","journal-title":"Blood"},{"issue":"8","key":"1775_CR381","doi-asserted-by":"publisher","first-page":"9655","DOI":"10.1002\/cam4.5916","volume":"12","author":"K Pei","year":"2023","unstructured":"Pei K, Xu H, Wang P, Gan W, Hu Z, Su X, et al. Anti-CLL1-based CAR T-cells with 4-1-BB or CD28\/CD27 stimulatory domains in treating childhood refractory\/relapsed acute myeloid leukemia. Cancer Med. 2023;12(8):9655\u201361.","journal-title":"Cancer Med"},{"issue":"16","key":"1775_CR382","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","volume":"390","author":"Y Hu","year":"2024","unstructured":"Hu Y, Zhang M, Yang T, Mo Z, Wei G, Jing R, et al. Sequential CD7 CAR T-Cell therapy and allogeneic HSCT without GVHD prophylaxis. N Engl J Med. 2024;390(16):1467\u201380.","journal-title":"N Engl J Med"},{"issue":"1","key":"1775_CR383","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/ejh.14104","volume":"112","author":"XY Wang","year":"2024","unstructured":"Wang XY, Bian MR, Lin GQ, Yu L, Zhang YM, Wu DP. Tandem bispecific CD123\/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia. Eur J Haematol. 2024;112(1):83\u201393.","journal-title":"Eur J Haematol"},{"issue":"Supplement 1","key":"1775_CR384","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1182\/blood-2018-99-110579","volume":"132","author":"F Liu","year":"2018","unstructured":"Liu F, Cao Y, Pinz K, Ma Y, Wada M, Chen K, et al. First-in-human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical trial. Blood. 2018;132(Supplement 1):901.","journal-title":"Blood"},{"issue":"15_suppl","key":"1775_CR385","doi-asserted-by":"publisher","first-page":"10511","DOI":"10.1200\/JCO.2020.38.15_suppl.10511","volume":"38","author":"H Newman","year":"2020","unstructured":"Newman H, Barz Leahy AE, Li Y, Liu H, Myers RM, DiNofia AM, et al. CD19-targeted chimeric antigen receptor (CAR) T cells in CNS relapsed acute lymphoblastic leukemia (ALL). J Clin Oncol. 2020;38(15_suppl):10511\u201310511.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1775_CR386","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"9","key":"1775_CR387","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.22.00642","volume":"41","author":"TW Laetsch","year":"2023","unstructured":"Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, et al. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41(9):1664\u20139.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10299","key":"1775_CR388","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet Lond Engl. 2021;398(10299):491\u2013502.","journal-title":"Lancet Lond Engl"},{"issue":"5","key":"1775_CR389","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","volume":"146","author":"CW Freyer","year":"2020","unstructured":"Freyer CW, Porter DL. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol. 2020;146(5):940\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1775_CR390","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"132","key":"1775_CR391","doi-asserted-by":"publisher","first-page":"4193","DOI":"10.1182\/blood-2018-99-110194","volume":"29","author":"NN Shah","year":"2018","unstructured":"Shah NN, Zhu F, Taylor C, Schneider D, Krueger W, Worden A, et al. A phase 1 study with point-of-care manufacturing of dual targeted, tandem anti-CD19, anti-CD20 chimeric antigen receptor modified T (CAR-T) cells for relapsed, refractory, non-hodgkin lymphoma. Blood. 2018;29(132):4193.","journal-title":"Blood"},{"key":"1775_CR392","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.2147\/OTT.S235882","volume":"13","author":"J Hua","year":"2020","unstructured":"Hua J, Qian W, Wu X, Zhou L, Yu L, Chen S, et al. Sequential infusion of Anti-CD22 and Anti-CD19 chimeric antigen receptor T cells for a pediatric Ph-like B-all patient that relapsed after cart-cell and haplo-HSCT therapy: A case report and review of literature. OncoTargets Ther. 2020;13:2311\u20137.","journal-title":"OncoTargets Ther"},{"issue":"1","key":"1775_CR393","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","volume":"13","author":"H Dai","year":"2020","unstructured":"Dai H, Wu Z, Jia H, Tong C, Guo Y, Ti D, et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol OncolJ Hematol Oncol. 2020;13(1):30.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"9","key":"1775_CR394","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3389\/fonc.2019.00146","volume":"12","author":"NN Shah","year":"2019","unstructured":"Shah NN, Maatman T, Hari P, Johnson B. Multi targeted CAR-T cell therapies for B-cell malignancies. Front Oncol. 2019;12(9):146.","journal-title":"Front Oncol"},{"issue":"12","key":"1775_CR395","doi-asserted-by":"publisher","first-page":"979","DOI":"10.2217\/imt-2017-0062","volume":"9","author":"IB Riaz","year":"2017","unstructured":"Riaz IB, Zahid U, Kamal MU, Husnain M, McBride A, Hua A, et al. Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: A systematic review and meta-analysis. Immunotherapy. 2017;9(12):979\u201393.","journal-title":"Immunotherapy"},{"issue":"12","key":"1775_CR396","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1038\/s41375-019-0488-7","volume":"33","author":"J Pan","year":"2019","unstructured":"Pan J, Niu Q, Deng B, Liu S, Wu T, Gao Z, et al. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Leukemia. 2019;33(12):2854\u201366.","journal-title":"Leukemia"},{"issue":"5","key":"1775_CR397","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1182\/blood-2015-06-650812","volume":"126","author":"DM Davies","year":"2015","unstructured":"Davies DM, Maher J. TSLPR: A new CAR in the showroom for B-ALL. Blood. 2015;126(5):567\u20139.","journal-title":"Blood"},{"issue":"3","key":"1775_CR398","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","volume":"130","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017;130(3):285\u201396.","journal-title":"Blood"},{"issue":"6","key":"1775_CR399","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","volume":"76","author":"X Liu","year":"2016","unstructured":"Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S, et al. A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res. 2016;76(6):1578\u201390.","journal-title":"Cancer Res"},{"issue":"12","key":"1775_CR400","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.jtct.2024.09.024","volume":"30","author":"R Ram","year":"2024","unstructured":"Ram R, Amit O, Perry C, Herishanu Y, Avivi I, Sarid N, et al. Addition of nivolumab tailored by expansion of CAR-T cells in patients with stable\/progressive large B cell lymphoma at lymphodepletion-a phase 2, prospective interventional study. Transplant Cell Ther. 2024;30(12):1178\u201388.","journal-title":"Transplant Cell Ther"},{"issue":"13","key":"1775_CR401","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1182\/blood.2023022204","volume":"143","author":"LC Hill","year":"2024","unstructured":"Hill LC, Rouce RH, Wu MJ, Wang T, Ma R, Zhang H, et al. Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed\/refractory mature T-cell lymphomas. Blood. 2024;143(13):1231\u201341.","journal-title":"Blood"},{"key":"1775_CR402","first-page":"1","volume":"1","author":"R Kadirkamanathan","year":"2025","unstructured":"Kadirkamanathan R, Georgiadis C, Kloos A, Joshi A, Etuk A, Preece R, et al. Base edited \u201cuniversal\u201d donor CAR T-cell strategies for acute myeloid leukaemia. Leukemia. 2025;1:1\u201310.","journal-title":"Leukemia"},{"issue":"7","key":"1775_CR403","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1002\/ijc.32269","volume":"145","author":"S Oelsner","year":"2019","unstructured":"Oelsner S, Waldmann A, Billmeier A, R\u00f6der J, Lindner A, Ullrich E, et al. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth. Int J Cancer. 2019;145(7):1935\u201345.","journal-title":"Int J Cancer"},{"key":"1775_CR404","unstructured":"Bui TA, Mei H, Sang R, Ortega DG, Deng W. Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment. eBioMedicine [Internet]. 2024 Aug 1 [cited 2025 May 22]: [106 p.]. Available from: https:\/\/www.thelancet.com\/journals\/ebiom\/article\/PIIS2352-3964(24)00302-5\/fulltext."},{"key":"1775_CR405","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2025.101612","volume":"25","author":"Z Song","year":"2025","unstructured":"Song Z, Zhou Y, Wang B, Geng Y, Tang G, Wang Y, et al. In vivo production of CAR T cell: opportunities and challenges. Genes Dis. 2025;25:101612.","journal-title":"Genes Dis"},{"issue":"9","key":"1775_CR406","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1182\/blood.2024024523","volume":"144","author":"CJ Nicolai","year":"2024","unstructured":"Nicolai CJ, Parker MH, Qin J, Tang W, Ulrich-Lewis JT, Gottschalk RJ, et al. In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand. Blood. 2024;144(9):977\u201387.","journal-title":"Blood"},{"issue":"1","key":"1775_CR407","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2558403","volume":"21","author":"Y Huang","year":"2025","unstructured":"Huang Y, Cao R, Wang S, Chen X, Ping Y, Zhang Y. In vivo CAR-T cell therapy: new breakthroughs for cell-based tumor immunotherapy. Hum Vaccin Immunother. 2025;21(1):2558403.","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"1775_CR408","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1158\/0008-5472.CAN-12-3558","volume":"73","author":"YH Chang","year":"2013","unstructured":"Chang YH, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res. 2013;73(6):1777\u201386.","journal-title":"Cancer Res"},{"key":"1775_CR409","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.611163","volume":"11","author":"P Schmidt","year":"2020","unstructured":"Schmidt P, Raftery MJ, Pecher G. Engineering NK cells for CAR therapy-recent advances in gene transfer methodology. Front Immunol. 2020;11:611163.","journal-title":"Front Immunol"},{"issue":"Supplement 1","key":"1775_CR410","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2020-134625","volume":"136","author":"C Bachier","year":"2020","unstructured":"Bachier C, Borthakur G, Hosing C, Blum W, Rotta M, Ojeras P, et al. A Phase 1 Study of NKX101, an allogeneic CAR natural killer (NK) cell therapy, in subjects with relapsed\/refractory (R\/R) acute myeloid leukemia (AML) or Higher-risk myelodysplastic syndrome (MDS). Blood. 2020;136(Supplement 1):42\u20133.","journal-title":"Blood"},{"issue":"1","key":"1775_CR411","first-page":"119","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan K, Farrukh H, Chittepu VCSR, Xu H, Pan CX, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res CR. 2022;41(1):119.","journal-title":"J Exp Clin Cancer Res CR"},{"issue":"10473","key":"1775_CR412","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","volume":"405","author":"A Ghobadi","year":"2025","unstructured":"Ghobadi A, Bachanova V, Patel K, Park JH, Flinn I, Riedell PA, et al. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet Lond Engl. 2025;405(10473):127\u201336.","journal-title":"Lancet Lond Engl"},{"issue":"3","key":"1775_CR413","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial. Nat Med. 2024;30(3):772\u201384.","journal-title":"Nat Med"},{"issue":"7","key":"1775_CR414","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","volume":"25","author":"AG Chapuis","year":"2019","unstructured":"Chapuis AG, Egan DN, Bar M, Schmitt TM, McAfee MS, Paulson KG, et al. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. Nat Med. 2019;25(7):1064\u201372.","journal-title":"Nat Med"},{"key":"1775_CR415","unstructured":"EudraCT Number 2006\u2013004950\u201325 - Clinical trial results - EU Clinical Trials Register [Internet]. [cited 2025 Oct 14]. Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-004950-25\/results."},{"issue":"Supplement_1","key":"1775_CR416","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2019-128044","volume":"134","author":"EC Morris","year":"2019","unstructured":"Morris EC, Tendeiro-Rego R, Richardson R, Fox TA, Sillito F, Holler A, et al. A phase i study evaluating the safety and persistence of allorestricted WT1-TCR gene modified autologous t cells in patients with high-risk myeloid malignancies unsuitable for allogeneic stem cell transplantation. Blood. 2019;134(Supplement_1):1367.","journal-title":"Blood"},{"key":"1775_CR417","doi-asserted-by":"publisher","unstructured":"van Balen P, Jedema I, van Loenen MM, de Boer R, van Egmond HM, Hagedoorn RS, et al. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study. Front Immunol [Internet]. 2020 Aug 20 [cited 2025 Oct 13]: [11 p.]. Available from: https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2020.01804\/full.","DOI":"10.3389\/fimmu.2020.01804\/full"},{"issue":"18","key":"1775_CR418","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.3390\/cancers13184519","volume":"13","author":"D Campillo-Davo","year":"2021","unstructured":"Campillo-Davo D, Anguille S, Lion E. Trial watch: adoptive TCR-engineered t-cell immunotherapy for acute myeloid leukemia. Cancers. 2021;13(18):4519.","journal-title":"Cancers"},{"issue":"15","key":"1775_CR419","doi-asserted-by":"publisher","first-page":"1487782","DOI":"10.3389\/fimmu.2024.1487782","volume":"8","author":"J Li","year":"2024","unstructured":"Li J, Zhang Y, Fu T, Xing G, Cai H, Li K, et al. Clinical advances and challenges associated with TCR-T cell therapy for cancer treatment. Front Immunol. 2024;8(15):1487782.","journal-title":"Front Immunol"},{"issue":"12","key":"1775_CR420","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/bloodadvances.2024014105","volume":"9","author":"S Gore","year":"2025","unstructured":"Gore S, Blyth E, Bleakley M, Lee K, Micklethwaite K, Gowrishankar K. Current developments in T-cell receptor therapy for acute myeloid leukemia. Blood Adv. 2025;9(12):3069\u201389.","journal-title":"Blood Adv"},{"key":"1775_CR421","unstructured":"Kovecses O, Mercier FE, McKeague M. Nucleic acid therapeutics as differentiation agents for myeloid leukemias. Leukemia [Internet]. 2024 Feb 29 [cited 2024 May 31]. Available from: https:\/\/www.nature.com\/articles\/s41375-024-02191-0."},{"issue":"10423","key":"1775_CR422","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(23)01724-5","volume":"403","author":"U Platzbecker","year":"2024","unstructured":"Platzbecker U, Santini V, Fenaux P, Sekeres MA, Savona MR, Madanat YF, et al. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): A multinational, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2024;403(10423):249\u201360.","journal-title":"Lancet Lond Engl"},{"issue":"3","key":"1775_CR423","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/bjh.15547","volume":"183","author":"AG Seto","year":"2018","unstructured":"Seto AG, Beatty X, Lynch JM, Hermreck M, Tetzlaff M, Duvic M, et al. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. Br J Haematol. 2018;183(3):428\u201344.","journal-title":"Br J Haematol"},{"issue":"4","key":"1775_CR424","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s10637-013-9935-x","volume":"31","author":"HP Erba","year":"2013","unstructured":"Erba HP, Sayar H, Juckett M, Lahn M, Andre V, Callies S, et al. Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). Invest New Drugs. 2013;31(4):1023.","journal-title":"Invest New Drugs"},{"issue":"24","key":"1775_CR425","doi-asserted-by":"publisher","first-page":"6150","DOI":"10.1158\/1078-0432.CCR-10-1932","volume":"16","author":"DC Talbot","year":"2010","unstructured":"Talbot DC, Ranson M, Davies J, Lahn M, Callies S, Andr\u00e9 V, et al. Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: A proof-of-concept, first-in-human dose study. Clin Cancer Res Off J Am Assoc Cancer Res. 2010;16(24):6150\u20138.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"28","key":"1775_CR426","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1200\/JCO.2009.21.8172","volume":"27","author":"AD Schimmer","year":"2009","unstructured":"Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, et al. Phase I\/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(28):4741\u20136.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1775_CR427","doi-asserted-by":"crossref","unstructured":"Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta G 3139, GC 3139, oblimersen sodium. Drugs RD. 2007;8(5):321\u201334.","DOI":"10.2165\/00126839-200708050-00006"},{"issue":"2","key":"1775_CR428","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1182\/blood-2002-06-1899","volume":"101","author":"G Marcucci","year":"2003","unstructured":"Marcucci G, Byrd JC, Dai G, Klisovic MI, Kourlas PJ, Young DC, et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood. 2003;101(2):425\u201332.","journal-title":"Blood"},{"issue":"7","key":"1775_CR429","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.leukres.2005.10.025","volume":"30","author":"J Moore","year":"2006","unstructured":"Moore J, Seiter K, Kolitz J, Stock W, Giles F, Kalaycio M, et al. A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Leuk Res. 2006;30(7):777\u201383.","journal-title":"Leuk Res"},{"key":"1775_CR430","unstructured":"Inc PT. ProNAi Reports Interim Data from Wolverine Phase 2 Trial of PNT2258 in DLBCL [Internet]. [cited 2024 May 31]. Available from: https:\/\/www.prnewswire.com\/news-releases\/pronai-reports-interim-data-from-wolverine-phase-2-trial-of-pnt2258-in-dlbcl-581947101.html."},{"issue":"4","key":"1775_CR431","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1200\/JCO.1996.14.4.1320","volume":"14","author":"MR Bishop","year":"1996","unstructured":"Bishop MR, Iversen PL, Bayever E, Sharp JG, Greiner TC, Copple BL, et al. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol. 1996;14(4):1320\u20136.","journal-title":"J Clin Oncol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01775-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01775-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01775-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T17:03:16Z","timestamp":1768496596000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-025-01775-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,11]]},"references-count":431,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1775"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01775-2","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,11]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}